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ABSTRACT
DNA-minor groove binding small molecules have been extensively developed to achieve
higher binding affinity and specificity. Polyamides are a class of small molecules that can be
programmed to target any predetermined DNA sequence. The development of hairpin polyamides
along with introduction of β-alanine substituents, has greatly enhanced the DNA binding properties
of these molecules. Yet the correlation between β-insert and binding properties remains unclear.
On the other hand, the design of small-size, fluorescent hybrid polyamides has facilitated cell
studies due to their ease of observation. There is a strong need to expand the DNA recognition

sites of such molecules and extend their biological applications. This dissertation has explored the
systematic design and synthesis of eight-ring hairpin polyamides as well as the modified PyrAzaHx hybrid polyamides. Comprehensive biophysical and biochemical tools were employed to
evaluate their binding properties. The effects of β-alanine and N-terminal cationic groups on
hairpin polyamides-DNA binding have been discussed. The binding properties of modified PyrAzaHx polyamides were explored. Altogether, the work provided fundamental guidance for the
prediction of binding properties of similar molecules as well as strategies for the design of more
competitive molecules.
Transcription factors bind to specific DNA sequences in the major groove and regulate
gene expression. Abnormal expression of transcription factors is involved in the development of
many serious diseases. Precise control of gene expression by targeting transcription factors can be
an alternative therapeutic approach. Polyamides bind to DNA with affinities comparable to
proteins, empowering them with the ability to interfere with transcription factors at specific DNA
binding site and consequently altering the gene expression level. In this dissertation, the effect of
polyamides on the binding of transcription factor PU.1 was studied. Abnormal expression of PU.1
is involved in the development of acute myeloid leukemia (AML). A positive correlation was
established between eight-ring polyamide binding affinity and inhibition efficacy for PU.1. A noninhibitor polyamide FH1024 was identified and the mechanism of action among polyamide, DNA
and PU.1 was explored. The studies showed strong evidence of the capability of polyamides
serving as drug agents. This work also established solid basis for the further cell studies.
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1

INTRODUCTION

DNA carries genetic information in living organisms and usually assumes a B-form, righthanded double helical structure (1). The genetic information is delivered through a series of
cellular events like DNA replication, transcription and translation. Among those, transcription is
the process of converting DNA into messenger RNA, during which a range of proteins, including
transcription factors, are recruited to facilitate and regulate the process. The precise operation of
transcription is essential for maintaining cellular homeostasis (2). In fact, abnormal regulation of
gene transcription is found to be involved in a number of devastating health issues such as cancer
and infectious diseases (3). Transcription factors play an important role in gene regulation and
their activities are often altered in cancer cells due to mutations, abnormal signaling, and
posttranslational modifications (4). Therefore, transcription factors are an attractive therapeutic
target point in drug development. Useful molecular tools that enables the accurate control of gene
expression by directly or indirectly targeting transcription factors can be a potential approach to
treating those serious conditions. Binding of transcription factors to specific DNA sequences is a
crucial step to recruiting accessory proteins and the subsequent transcriptional activities (2).
Specific DNA-binding small molecules can be used as anti-cancer agents to interfere with
transcription factor-DNA interactions and thus rectify the abnormal gene expression.
1.1

DNA minor groove-targeting small molecules
1.1.1

Development of β-alanine inserted hairpin polyamides

N-methylpyrrole (Py), N-methylimidazole (Im) polyamides (PAs) are a class of
programmable synthetic small molecules that interact with DNA by binding to the minor groove
of specific DNA sites. Polyamides are originally derived from the naturally existing antibiotics:
netropsin and distamycin A (5, 6). These natural molecules are composed of two or three pyrrole
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heterocycles linked with amide binds (Figure 1.1) and bind the AT rich regions of DNA
preferentially in a 1:1 ratio (7, 8). These molecules interact with DNA through hydrogen bonding,
van der Waals forces and electrostatic interactions to achieve stability and specificity of the
complex. Based on the X-ray analysis of netropsin-DNA complex, Dickerson and coworkers
established the molecular foundation of the base specificity of netropsin. That is, the binding
preference of netropsin to four or more consecutive AT base pairs is achieved not by hydrogen
bonding but by the close van der Waals contacts between C3-H of pyrrole and C2-H of adenine.
They further proposed that replacement of pyrrole with imidazole, that is changing C3-H to N,
would enable the modified new molecule to recognize a G/C base pair, and therefore, any short
DNA sequences (9). This work is fundamental for the development of polyamides that are capable
of expanding the DNA recognition site. Wemmer and coworkers later found in an NMR
experiment that titration of DNA with distamycin A at high drug to DNA ratio (>1:1) generated a
single, stable drug-DNA complex that was different from the complexes formed at low drug to
DNA ratio (< 1:1). Their NMR structure revealed that distamycin A formed a 2:1 antiparallel
stacked dimer with DNA (10). These discoveries have laid solid foundation for the evolution of
polyamides. Subsequently, Lown, Devan, Wemmer and coworkers were able to synthesize a
netropsin analogue that incorporated imidazole at the N-terminus and demonstrated that the new
molecule was able to recognize mixed A/T and G/C sequences as a 2:1 antiparallel side-by-side
dimer (11-13). The result not only proved the previous hypothesis but also significantly facilitated
the formation of the widely-recognized DNA binding rules. Briefly, Py/Py recognizes A/T or T/A
base pairs; Py/Im recognizes C/G base pairs; Im/Py recognizes G/C base pairs. Since Py/Py cannot
distinguish A/T from T/A, Dervan and coworkers introduced an N-methyl-3-hydroxypyrrole (Hp)
moiety by replacing C3-H with C3-OH on the pyrrole unit of polyamides. Although Hp was able
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to bind to T through hydrogen bonding and enable the molecule to distinguish T/A from A/T, it is
not widely used due to the difficulty in synthesis and its instability in both solid and solution form
(14-19). Based on the DNA recognition rules, we are able to design polyamides that can target any
short DNA sequences.
Inspired by the dimer mode of binding as well as to enhance the binding affinities,
polyamides have been developed into various forms, for example, hairpin, H-pin, U-pin and cyclic
polyamides (20-23). Among these structures, hairpin polyamides are most commonly used in
research because of their versatility and ease of synthesis (23). Hairpin polyamides consist of two
polyamide strands that are covalently linked by γ-aminobutyric acid (γ-turn) from the C-terminus
of one polyamide to the N-terminus of the other (24, 25). (Figure 1.2) Binding of hairpin
polyamides can assume two orientations: N-terminus of polyamide aligns with 5’ side of DNA
(forward binding) or 3’ side of DNA (reverse binding) (24, 26-28). Hairpin polyamides bind to
DNA following the recognition rules with significantly enhanced affinity (almost 100-fold higher
compared to the naturally existing distamycin A) and specificity. This modification has
empowered polyamides to achieve DNA-binding affinities comparable to those of DNA-binding
proteins (28).
In order to expand the length of the DNA recognition site and therefore, to achieve higher
specificity, hairpin polyamides have to be elongated accordingly by increasing the number of Py
and Im heterocycles. Studies have shown that the limit of the number of rings on either polyamide
strand is five for the DNA to tolerate (23). Hairpin polyamides longer than that become over curved
(compared to the curvature of the B-form double strand DNA helix) and too stringent to
accommodate themselves to the DNA minor groove. As a result, both binding affinity and
specificity are sacrificed. This issue was tackled by introducing β-alanine (β) into the hairpin
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polyamide building block as a flexible motif to replace one or more Py rings. Incorporation of βalanine relaxes the overall polyamide structure and can restore both the binding affinity and
specificity (29, 30). β-alanine functions as a Py and forms hydrogen bonds with A and T.
The recognition activity of small molecules is primarily determined by their structures.
Until now, the molecular basis of the interactions between β-containing hairpin polyamides and
DNA is still unclear. The number and position of β in polyamides largely affect their binding
affinity, specificity as well as orientation. Bashkin and coworkers found that not all β-inserted
polyamides enhance binding affinity (31-33). Hence, a thorough investigation of the effects of the
composition of hairpin polyamides on their DNA binding activities is in great need.
1.1.2

Development of short Pyr-AzaHx hybrid polyamides

Polyamides are developed to realize their optimal biological functions in living organisms,
which requires efficient cell uptake and nuclear localization. The cell permeability of prototypical
polyamides varies depending on the cell types, polyamide structure, composition, and size (3437). Typically, hairpin polyamides are considered to be associated with poor nuclear localization
due to their larger size, lower solubility and stability (38). On the other hand, cell study of the
biological effects of polyamides requires conjugation of fluorescent dyes due to its lack of intrinsic
fluorescence. Although significant progress has been made using this method, molecules that could
enable the direct observation of nuclear localization would eliminate extra concerns about the
effect of fluorescent dyes on the overall structure and function of polyamides (39-44).
Lee, Wilson and coworkers sought an alternative approach based on the molecular
recognition of triamides (45) (Figure 1.3), by attaching an intrinsically fluorescent Hx moiety (2(p-anisyl)-benzimidazole) to a consecutive I-P, P-P or P-I heterocycles (Figure 1.3) The resulted
hybrid Hx-amides bind to DNA as a stacked, side-by-side, antiparallel dimer. Hx expands along
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two continuous dinucleotides and behaves predictably similarly to P-P or f-P (46, 47). The novel
small-sized hybrid polyamides retained the binding affinity and specificity and also exerted better
solubility and cell uptake activities. More importantly, these polyamides greatly facilitated the
direct observation of nuclear localization with their fluorescent properties. The Lee, Wilson group
further built upon the solid Hx base, an AzaHx moiety (2-(p-anisyl)-4-azabenzimidazole), to
extend the DNA recognition repertoire (48) (Figure 1.3). AzaHx differentiates itself from Hx in
that it mimics P-I or f-I and can target AG, TG or CG dinucleotides. Of the most importance is
that this modification extended the recognition of central bases from CG to GC as well.
1.2

DNA major groove-targeting transcription factors
Transcription factors are of vital importance in the first level of regulation of transcription.

The process requires the binding of transcription factors to defined promoter or enhancer regions
to recruit subsequent transcription machinery (2, 49). ETS (E26 transformation specific) family of
transcription factors are a group of functionally diverse proteins that share a conserved 85-residue
domain, which specifically recognizes purine rich sequences containing a 5’-GGA(A/T)-3’
consensus core (50). Of those proteins, PU.1 (Purine rich box 1) is expressed selectively on B
cells, myeloid cells and macrophages and regulates several genes that are involved in cell
differentiation and the immune system (51). Over- or under- regulation of PU.1 expression is
associated with the induction of acute myeloid leukemia (AML) (52-55). Regulating PU.1
expression level in a controllable way, therefore, has been considered a feasible approach for the
treatment of AML.
The

B

motif

of

the

Ig2-4

enhancer

(B

promoter

site:

5’-

CCAAATAAAAGGAAGTGAAACCAAG-3’) has been widely used in research as the classical
PU.1 binding cognate site. Stability of PU.1-DNA complex is a crucial determining factor of the
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transcriptional efficacy in vivo. Studies have shown that the promoter activity is strongly correlated
with the binding affinity of PU.1 (56). In a sequence selectivity study, Poon demonstrated that the
binding affinity of PU.1-DNA is affected by flanking sequences up to three bases upstream and/or
two bases downstream of the core consensus, using B site as reference. While most of the mutated
sequences lowered the binding affinity, the 3’ side mutants generated the poorest binding of all
(50).
Small molecules have been used to target the flanking sequences of the promoter region
and to allosterically compete or cooperate with transcription factors binding to DNA. In the case
of PU.1, most studies have focused on the AT rich region at the 5’ side of the 5’-GGAA-3’
sequence. Applications of natural agent distamycin as well as a class of small heterocyclic
diamidines have been shown to successfully inhibit PU.1 from binding to the cognate site (57, 58).
To this date, there has hardly been any report on the effect of the 3’ side binding molecules,
provided that the 3’ side is of equal or even more importance to the binding of PU.1.
1.3

Objectives
This dissertation took the effort to systematically design and synthesize a set of eight-ring

hairpin polyamides with modifications not only in the arrangement of β-alanine but also the Nterminus charged motif. By evaluating the DNA binding properties of these molecules, this work
established a general binding pattern for eight-ring hairpin polyamides, which expanded our
understanding of the molecular recognition of hairpin polyamides as well as provided clear
guidance for the optimization of rational polyamide design in the future.
With the aim of expanding the DNA recognition repertoire of fluorescent small hybrid
polyamides, this dissertation attempted to recognize 5’-GGCC-3’ DNA sequence by designing a
set of pyridine-AzaHx polyamides. Assessment of their binding properties revealed that the Pyr-
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AzaHx polyamides do not recognize the desired GG dinucleotides, but behave similarly to AzaHx
polyamide with significantly enhanced binding affinity.
Over the years of development, modified polyamides are able to achieve DNA-binding
affinities that rival those of DNA-binding proteins (34, 35). Binding of polyamides has also been
shown to cause DNA conformational change in a way that the minor groove is widened while the
major groove is compressed (22, 59). This dissertation took the pioneering effort in investigating
the effect of a set of eight-ring hairpin polyamides that target the 3’ side immediate flanking
sequence of the PU.1 binding site, on the binding of PU.1. The work established a positive linear
correlation between the binding affinity and inhibition efficacy of polyamides. More importantly,
it discovered and characterized a close analogue of the polyamide that potentially enhances PU.1
binding to DNA. This property of polyamides has never been characterized before.
In summary, this dissertation employees a wide selection of biochemical and biophysical
techniques including SPR, ESI-MS, thermal melting, EMSA, CD, DNase I footprinting and so on,
for the exploration of the binding properties of two different types of polyamide derivatives. Both
the established binding pattern of the classical hairpin polyamides and the enhanced binding of the
small-sized Pyr-AzaHx hybrid polyamides are valuable references for the development of design
strategies of molecules with improved DNA binding properties and biological performance. The
investigation of PU.1-DNA, polyamide-DNA interactions uncovers possibly new molecular
mechanisms of the mode of action of these interactions, which can significantly expedite the design
of biologically relevant agents when understood thoroughly.
1.4
1

References
J. D. Watson, and F.H. Crick. Genetical implications of the structure of deoxyribonucleic acid.
Nature., 1953, 171, 964-967.

8

2

C. Yan, and P.J. Higgins. Drugging the undruggable: transcription therapy for cancer. Biochim
Biophys Acta., 2013, 1835, 76-85.

3

L. H. Hurley, DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer.,
2002, 2, 188-200.

4

A. G. Papavassiliou, Transcription-factor-modulating agents: precision and selectivity in drug
design. Mol Med Today., 1998, 4, 358-366.

5

A. C.Finlay, F. A. Hochstein, B. A. Sobin, and F. X. Murphy. Netropsin, a new antibiotic
produced by a Streptomyces. J. Am. Chem. Soc., 1951, 73, 341-343.

6

F. Arcamone, S. Penco, P. Orezzi, V. Nicolella, and A. Pirelli. Structure and Synthesis of
Distamycin A. Nature., 1964, 203, 1064-1065.

7

A. Hahn, Molecur mechanism of action of the radioprotective substance WR 2721. Radiat
Environ Biophys., 1975, 11, 265-269.

8

C. Zimmer, and U. Wahnert. Nonintercalating DNA-binding ligands: specificity of the
interaction and their use as tools in biophysical, biochemical and biological investigations of
the genetic material. Prog Biophys Mol Biol., 1986, 47, 31-112.

9

M. L. Kopka, C. Yoon, D. Goodsell, P. Pjura, and R. E. Dickerson. The molecular origin of
DNA-drug specificity in netropsin and distamycin. Proc Natl Acad Sci U S A., 1985, 82, 13761380.

10 J. G. Pelton, and D .E. Wemmer, Structural characterization of a 2:1 distamycin
A.d(CGCAAATTGGC) complex by two-dimensional NMR. Proc Natl Acad Sci U S A., 1989,
86, 5723-5727.

9

11 W. S. Wade, M. Mrksich, and P. B. Dervan. Design of Peptides That Bind in the Minor Groove
of DNA at 5'-(a,T)G(a,T)C(a,T)-3' Sequences by a Dimeric Side-by-Side Motif. J Am Chem
Soc., 1992, 114, 8783-8794.
12 M. Mrksich, W. S. Wade, T. J. Dwyer, B. H. Geierstanger, D. E. Wemmer and P. B. Dervan.
Antiparallel side-by-side dimeric motif for sequence-specific recognition in the minor groove
of DNA by the designed peptide 1-methylimidazole-2-carboxamide netropsin. Proc Natl Acad
Sci U S A., 1992, 89, 7586-7590.
13 W. S. Wade, M. Mrksich, and P. B. Dervan. Binding affinities of synthetic peptides, pyridine2-carboxamidonetropsin and 1-methylimidazole-2-carboxamidonetropsin, that form 2:1
complexes in the minor groove of double-helical DNA. Biochemistry., 1993, 32, 1138511389.
14 S. White, J. W. Szewczyk, J. M. Turner, E. E. Barid, and P. B. Dervan. Recognition of the
four Watson-Crick base pairs in the DNA minor groove by synthetic ligands. Nature., 1998,
391, 468-471.
15 C. L., Kielkopf, S. White, J. W. Szewczyk, J. M. Turner, E. E. Barid, P. B. Dervan, and D. C.
Reese. A structural basis for recognition of A.T and T.A base pairs in the minor groove of BDNA. Science, 1998, 282, 111-115.
16 P. B. Dervan. Molecular recognition of DNA by small molecules. Bioorg Med Chem., 2001,
9, 2215-2235.
17 P. B. Dervan, and B. S. Edelson. Recognition of the DNA minor groove by pyrrole-imidazole
polyamides. Curr Opin Struct Biol., 2003, 13, 284-299.
18 C. Melander, R. Burnett, and J. M. Gottesfeld. Regulation of gene expression with pyrroleimidazole polyamides. J Biotechnol., 2004, 112, 195-220.

10

19 M. S. Blackledge, and C. Melander. Programmable DNA-binding small molecules. Bioorg
Med Chem., 2013, 21, 6101-6114.
20 M. Mrksich, and P. B. Dervan. Design of a Covalent Peptide Heterodimer for SequenceSpecific Recognition in the Minor-Groove of Double-Helical DNA. J Am Chem Soc., 1994,
116, 3663-3664.
21 A. Heckel, and P. B. Dervan. U-pin polyamide motif for recognition of the DNA minor
groove. Chemistry., 2003, 9, 3353-3366.
22 D. M. Chenoweth, and P. B. Dervan. Allosteric modulation of DNA by small molecules. Proc
Natl Acad Sci U S A., 2009, 106, 13175-13179.
23 Y. Kawamoto, T. Bando, and H. Sugiyama. Sequence-specific DNA binding Pyrroleimidazole polyamides and their applications. Bioorg Med Chem., 2018, 26,1393-1411.
24 M. Mrksich, M. E. Parks, and P. B. Dervan. Hairpin Peptide Motif - a New Class of
Oligopeptides for Sequence-Specific Recognition in the Minor-Groove of Double-Helical
DNA. J Am Chem Soc., 1994, 116, 7983-7988.
25 C. L. Wu, W. Wang, L, Fang, and W. Su. Programmable pyrrole-imidazole polyamides: A
potent tool for DNA targeting. Chinese Chemical Letters., 2018, 29,1105-1112.
26 E. E. Baird, and P.B. Dervan. Solid phase synthesis of polyamides containing imidazole and
pyrrole amino acids. J Am Chem Soc., 1996, 118, 6141-6146.
27 N. R. Wurtz, Fmoc solid phase synthesis of polyamides containing pyrrole and imidazole
amino acids. Org Lett., 2001, 3,1201-1203.
28 J. W. Trauger, E. E. Baird, and P. B. Dervan. Recognition of DNA by designed ligands at
subnanomolar concentrations. Nature., 1996, 382, 559-561.

11

29 J. M. Turner, E. E. Baird, and P. B. Dervan. Recognition of seven base pair sequences in the
minor groove of DNA by ten-ring pyrrole-imidazole polyamide hairpins. J Am Chem Soc.,
1997, 119, 7636-7644.
30 J. M. Turner, S. E. Swalley, E. E. Baird, and P. B. Dervan. Aliphatic/aromatic amino acid
pairings for polyamide recognition in the minor groove of DNA. J Am Chem Soc., 1998, 120,
6219-6226.
31 J. K. Bashkin, K. Aston, J. P. Ramos, K. J. Koeller, R. Nanjunda, G. He, C. M. Dupureur, and
W. D. Wilson. Promoter scanning of the human COX-2 gene with 8-ring polyamides:
unexpected weakening of polyamide-DNA binding and selectivity by replacing an internal NMe-pyrrole with beta-alanine. Biochimie., 2013, 95,271-279.
32 S. Wang, K. Aston, K. J. Koeller, G. D. Harris, Jr. N. P. Rath, J. K. Bashkin, and W. D.
Wilson. Modulation of DNA-polyamide interaction by beta-alanine substitutions: a study of
positional effects on binding affinity, kinetics and thermodynamics. Org Biomol Chem., 2014,
12,7523-7536.
33 S. Wang, R. Nanjunda, K. Aston, J. K. Bashkin, and W. D. Wilson. Correlation of local effects
of DNA sequence and position of beta-alanine inserts with polyamide-DNA complex binding
affinities and kinetics. Biochemistry., 2012, 51,9796-9806.
34 T. P. Best, B. S. Edelson, N. G. Nickols, and P. B. Dervan. Nuclear localization of pyrroleimidazole polyamide-fluorescein conjugates in cell culture. Proc Natl Acad Sci U S A., 2003,
100, 12063-12068.
35 B. S. Edelson, T. P. Best, B. Olenyuk, N. G. Nickols, R. M. Doss, S. Foister, A. Heckel, and
P. B. Dervan. Influence of structural variation on nuclear localization of DNA-binding
polyamide-fluorophore conjugates. Nucleic Acids Res., 2004, 32, 2802-2818.

12

36 J. M. Belitsky, S. J. Leslie, P. S. Arora, T. A. Beerman, and P. B. Dervan. Cellular uptake of
N-methylpyrrole/N-methylimidazole polyamide-dye conjugates. Bioorg Med Chem., 2002,
10, 3313-3318.
37 S. Nishijima, K. Shinohara, T. Bando, M. Minoshima, G. Kashiwazaki, and H. Sugiyama.
Cell permeability of Py-Im-polyamide-fluorescein conjugates: Influence of molecular size
and Py/Im content. Bioorg Med Chem., 2010, 18, 978-983.
38 A. Franks, C. Tronrud, K. Kiakos, J. Kluza, M. Munde, T. Brown, H. Mackay, W. D. Wilson,
D. Hochhauser, J. A. Hartley, M. Lee. Targeting the ICB2 site of the topoisomerase IIalpha
promoter with a formamido-pyrrole-imidazole-pyrrole H-pin polyamide. Bioorg Med Chem.,
2010, 18, 5553-5561.
39 J. A. Raskatov, J. O. Szablowski, and P. B. Dervan, Tumor xenograft uptake of a pyrroleimidazole (Py-Im) polyamide varies as a function of cell line grafted. J Med Chem., 2014, 57,
8471-8476.
40 T. F. Martinez, J. W. Philips, K. K. Karanja, P. Polaczek, C. M. Wang, B. C. Li, J. L.
Campbell, and P. B. Dervan. Replication stress by Py-Im polyamides induces a non-canonical
ATR-dependent checkpoint response. Nucleic Acids Res., 2014, 42, 11546-11559.
41 J. A. Raskatov, J. W. Puckett, and P. B. Dervan. A C-14 labeled Py-Im polyamide localizes
to a subcutaneous prostate cancer tumor. Bioorg Med Chem., 2014, 22, 4371-4375.
42 J. S. Kang, J. L. Meier, and P. B. Dervan. Design of sequence-specific DNA binding
molecules for DNA methyltransferase inhibition. J Am Chem Soc., 2014, 136, 3687-3694.
43 J. L. Meier, D. C. Montgomery, and P. B. Dervan. Enhancing the cellular uptake of Py-Im
polyamides through next-generation aryl turns. Nucleic Acids Res., 2012, 40, 2345-2356.

13

44 T. Vaijayanthi, T. Bando, G. N. Pandian, and H. Sugiyama. Progress and prospects of pyrroleimidazole

polyamide-fluorophore

conjugates

as

sequence-selective

DNA

probes.

Chembiochem., 2012, 13, 2170-2185.
45 N. M. Le, A. M. Sielaff, A. J. Cooper, H. Mackay, T. Brown, M. Kotecha, C. O’Haire, D.
Hochhauser, M. Lee and J. A. Hartley. Binding of f-PIP, a pyrrole- and imidazole-containing
triamide, to the inverted CCAAT box-2 of the topoisomerase IIalpha promoter and modulation
of gene expression in cells. Bioorg Med Chem Lett., 2006, 16, 6161-6164.
46 S. Chavda, Y. Liu, B. Babu, R. Davis, A. Sieiaff, J. Ruprich, L. Westrate, C. Tronrud, A.
Ferguson, A. Franks, S. Tzou, C. Adkins, T. Rice, H. Mackay, J. Kluza, S. A. Tahir, S. Lin,
K. Kiakos, C. D. Bruce, W. D. Wilson, J. A. Hartley and M. Lee. Hx, a novel fluorescent,
minor groove and sequence specific recognition element: design, synthesis, and DNA binding
properties

of

p-anisylbenzimidazole-imidazole/pyrrole-containing

polyamides.

Biochemistry., 2011, 50, 3127-3136.
47 V. Satam, P. Patil, B. Babu, M. Gregory, M. Bowerman, M. Savagian, M. Lee, S. Tzou, K.
Olson, Y. Liu, J. Ramos, W. D. Wilson, J. P. Bingham, K. Kiakos, J. A. Hartley, and M. Lee.
Hx-amides:

DNA

sequence

recognition

by

the

fluorescent

Hx

(p-

anisylbenzimidazole)*pyrrole and Hx*imidazole pairings. Bioorg Med Chem Lett., 2013, 23,
1699-1702.
48 V. Satam, B. Babu, P. Patil, K. A. Brien, K. Olson, M. Savagian, M. Lee, M. Mepham, L. B.
Jobe, J. P. Bingham, L. Pett, S. Wang, M. Ferrara, C. D. Bruce, W. D. Wilson, M. Lee, J. A.
Hartley, and K. Kiakos. AzaHx, a novel fluorescent, DNA minor groove and G.C recognition
element: Synthesis and DNA binding properties of a p-anisyl-4-aza-benzimidazole-pyrroleimidazole (azaHx-PI) polyamide. Bioorg Med Chem Lett., 2015, 25, 3681-3685.

14

49 A. Melnick. Predicting the effect of transcription therapy in hematologic malignancies.
Leukemia., 2005, 19, 1109-1117.
50 G. M. Poon, and R. B. Macgregor, Jr. Base coupling in sequence-specific site recognition by
the ETS domain of murine PU.1. J Mol Biol., 2003, 328, 805-819.
51 J. Lloberas, C. Soler, and A. Celada. The key role of PU.1/SPI-1 in B cells, myeloid cells and
macrophages. Immunol Today., 1999, 20, 184-189.
52 E. W. Scott, R. C. Fisher, M. C. Olson, E. W. Kehrli, M. C. Simon, and H. Singh. PU.1
functions in a cell-autonomous manner to control the differentiation of multipotential
lymphoid-myeloid progenitors. Immunity., 1997, 6, 437-447.
53 F. Rosenbauer, K. Wagner, J. L. Kutok, H. Iwasaki, M. M. Le Beau, Y. Okuno, K. Akashi, S.
Fiering, and D. G. Tenen. Acute myeloid leukemia induced by graded reduction of a lineagespecific transcription factor, PU.1. Nat Genet., 2004, 36, 624-630.
54 E. W. Scott, M. C. Simon, J. Antastasi, and H. Singh. Requirement of transcription factor
PU.1 in the development of multiple hematopoietic lineages. Science., 1994, 265, 1573-1577.
55 D. L. Stirewalt, Fine-tuning PU.1. Nat Genet., 2004, 36, 550-551.
56 S. L. Li, W. Schlegel, A. J. Valente, and R. A. Clark. Critical flanking sequences of PU.1
binding sites in myeloid-specific promoters. J Biol Chem., 1999, 274, 32453-32460.
57 M. Munde, G. M. Poon, and W .D. Wilson. Probing the electrostatics and pharmacological
modulation of sequence-specific binding by the DNA-binding domain of the ETS family
transcription factor PU.1: a binding affinity and kinetics investigation. J Mol Biol., 2013, 425,
1655-1669.

15

58 M. Munde, S. Wang, A. Kumar, C. E. Stephens, A. A. Farahat, D. W. Boykin, W. D. Wilson,
and G. M. Poon. Structure-dependent inhibition of the ETS-family transcription factor PU.1
by novel heterocyclic diamidines. . Nucleic Acids Res., 2014, 42, 1379-1390.
59 Y. Wang, N. Ma, and G. Chen. Allosteric analysis of glucocorticoid receptor-DNA interface

induced by cyclic Py-Im polyamide: a molecular dynamics simulation study. PloS one., 2012,
7, e35159.
1.5

Tables and Figures

Figure 1.1 Structures of netropsin and distamycin.
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Figure 1.2 Structure of hairpin polyamide and its recognition to DNA (25).

Figure 1.3 Structures of triamide (f-IPI) and hybrid polyamides.
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2.1

Abstract
Minor-groove binding hairpin polyamides (PAs) bind specific DNA sequences. Synthetic

modifications can improve PA-DNA binding affinity and include flexible modules, such as βalanine (β) motifs to replace pyrroles (Py), and increasing compound charge using N-terminal
cationic substituents. To better understand the variations in kinetics and affinities caused by these
modifications on PA-DNA interactions, a comprehensive set of PAs with different numbers and
positions of β and different types of N-cationic groups was systematically designed and
synthesized to bind their cognate sequence, the λB motif. The λB motif is also a strong binding
promoter site of the major groove targeting transcription factor PU.1. The PA binding affinities
and kinetics were evaluated using a spectrum of powerful biophysical methods: thermal melting,
biosensor surface plasmon resonance and circular dichroism. The results show that β inserts affect
PA-DNA interactions in a number and position dependent manner. Specifically, a β replacement
between two imidazole heterocycles (ImβIm) generally strengthens binding. In addition, Nterminal cationic groups can accelerate the association between PA and DNA, but the bulky size
of TMG can cause steric hindrance and unfavourable repulsive electrostatic interactions in some
PAs. The future design of stronger binding PA requires careful combination of βs and cationic
substituents.
2.2

Introduction
Polyamides (PA) are heterocyclic cations that consist of N-methylpyrrole (Py) and N-

methylimidazole (Im) aromatic rings linked by amide bonds (1-4). They are potentially useful in
applications such as gene therapeutics and inhibiting protein-DNA interactions (5-7). Derived
from the natural DNA minor groove binding agents, netropsin and distamycin, PAs have been
developed extensively over the years to enhance their DNA-binding affinity and specificity. Even
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though targeting the relatively narrow DNA minor groove, distamycin was found to form 2:1
antiparallel stacked dimer complexes with AT-rich DNA (8). The finding led to the concept of
covalently linking two PA monomers by a flexible linker that can mimic the bend of a hairpin.
Therefore, hairpin PAs can form a 1:1 side-by-side complex with the two strands of DNA minor
groove at higher affinity and specificity than traditional PAs (1, 9-11). Based on the hydrogen
bonding interactions of the complex and its pairwise heterocycle stacking properties, general PADNA recognition rules were developed and have advanced molecular design (3, 10, 12). However,
challenges still exist, since elongating hairpin PAs to eight or more rings leads to an over-curved
structure which no longer matches the minor groove shape of B-form DNA. The resulting shape
mismatch for long PAs causes a loss of hydrogen bonding strength that erodes both binding affinity
and specificity (13, 14). Incorporating a flexible motif such as β-alanine (β) to serve as a
replacement of internal Py moieties has been reported to help compensate for the structural
incompatibility and improve binding (15-18). However, some literature results show a variety of
binding affinity effects of β-inserts, including a decrease in binding affinity of some PAs by the
introduction of βs. It is quite important to notice that the insertion of β at different positions of the
same molecule has been shown to have very diverse effects on binding affinity (17, 19-21). It is
essential, therefore, to understand the complex role of β insertion in PA-DNA interactions to guide
the molecular design of better PAs.
Another challenge of large size hairpin PAs which contain more than six heterocyclic
rings is aggregation and low solubility at high concentrations (20, 22, 23). The natural product,
netropsin, contains a cationic guanidine moiety at its N-terminus, which presumably enhances both
the solubility and its affinity to anionic DNA sequences (24). A previous study has demonstrated
that the replacement of the monocationic Dp group [3-(dimethylamino)propylamine] by a
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dicationic Ta group (3,3’-diamino-N-methyldipropylamine) could maintain the DNA binding
mode and affinity of eight-ring hairpin PAs as well as significantly reduce PA aggregation (20).
Bashkin and coworkers have also reported that guanidinyl-substituted PAs have better antiviral
activities against human papillomavirus (HPV) than traditional PAs (25). Thus, it is important to
incorporate cationic substituents into PA, explore their effects on PA-DNA binding interactions,
and better understand how to modulate the solution properties of PAs.
2.2.1

Compound Design

In order to evaluate the effects of β inserts and cationic substituents on PA-DNA
interactions, a series of hairpin PAs was systematically designed that covered reasonable internal
exchanges of Py to β (Fig. 2.1A). In parallel, cationic substituents were also added to each
counterpart with the exception of two molecules that have β inserts close to the C-terminus (Fig.
2.1A, KA2114 and KA2115). This is because β-alanine confers more flexibility to PAs when
inserted close to a terminus than when positioned internally. With one positive charge at the Nterminus and two positive charges at the C-terminus, strong electrostatic repulsions would be
expected to disrupt stacking of PA heterocycles and interfere with binding to the targeted DNA
site. For this reason, KA2114 and KA2115 do not have cationic substituted counterparts.
The molecules in Fig. 2.1A are categorized into two groups: β-alanine inserts and cationic
substituents, based on their modifications. To further assist data interpretation, all the heterocycles
were numbered from 1 to 8 starting from the N-terminus. The parent PA, KA2035, contains eight
heterocyclic rings and an N-terminal formamido group that is identical to that found in natural
product Distamycin A. In the β-alanine inserts group, analogs of KA2035 that contain a single β
replacement (KA2034 at ring 3, KA2041 at ring 6, and KA2114 at ring 7) and two βs (KA2040 at
rings 3 and 6, and KA2115 at rings 3 and 7) at three different Py positions have been developed
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and synthesized. In the cationic substituents group: KJK6162 has the same heterocyclic rings as
KA2035 but incorporates tetramethylguanidine (TMG) at the N-terminus. The TMG cationic Nterminal containing molecules also include FH1026 and FH1028, both of which have a single β
insert, but at rings number 6 and number 3, respectively. Another member in this group is FH1024,
which possesses the same composition with KA2040 and a TMG at the N-terminus.
The designed PA-DNA binding site is AGTGA. The binding site is contained in the λB
promoter region, to which transcription factor PU.1 binds. Therefore, λB sequence is chosen as
the target DNA sequence in this study to screen potential PU.1-DNA inhibitors in the future. This
is important in that PU.1 is involved in many physiological diseases such as auto-immune diseases
and acute myeloid leukemia (AML) (26, 27). Extensive biophysical studies were carried out with
the systematically designed compounds and their cognate and mutant DNAs. The results showed
that β-inserts affect PA-DNA binding affinity in a manner that is dependent on PA composition
and β position. For the current set of PA, a clear binding pattern between β-inserted PA and DNA
was developed. The effects of flanking base pairs on PA-DNA binding were also investigated.
2.3

Materials and Methods
2.3.1

DNA and Compound synthesis

All the DNA oligomers in this study were purchased from Integrated DNA Technologies,
Inc. (IDT, Coralville, IA) and the purity is checked by ESI-MS. The DNAs used are shown below:
λB

DNA:

5’-Biotin-CCAAATAAAAGGAAGTGAAACCAAGCTCTCTTGGTTTCAC

TTCCTTTTATTTGG-3’;SC1 DNA: 5’-Biotin-CGGCCAAGCCGGAAGTGAGTGCCTCTCG
GCACTCACTTCCGGCTTGGCCG-3’; GAGA mutant DNA: 5’-Biotin- CCAAATAAAAGA
GAGTGAAACCAAGCTCTCTTGGTTT CACTCTCTTTTATTTGG-3’
Short λB DNA: 5’-GGAAGTGAACCTCTGTTCACTTCC-3’
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Mutant 1: 5’-GGAAGAGAACCTCTGTTCACTTCC-3’
Mutant 2: 5’-GGAAGTGTACCTCTGTTCACTTCC-3’
Mutant 3: 5’-GGAAGTTAACCTCTGTTCACTTCC-3’
Mutant 4: 5’-GGAACTGAACCTCTGTTCACTTCC-3’
Mutant 5: 5’-GGAAGTCAACCTCTGTTCACTTCC-3’
The three long DNAs with biotin at 5’ were used for SPR experiments. The short λB DNA
was used for Thermal melting and Circular Dichroism experiments. The five mutant sequences
were used for Thermal melting.
Compound Synthesis Boc-β-alanine-PAM resin was purchased from Peptides
International. Polyamide building blocks, monomers or dimers, were purchased from A Chemtek,
Inc. (Worcester, MA) and purification of polyamides was done by the Boc-PAM solid phase
method as reported (28), with some modifications. In particular, dimer building blocks were
purchased from A Chemtek or were prepared in-house and used in place of sequential monomers.
This was especially the case when monomer coupling would have involved the poorlynucleophilic imidazole amino group from the growing, resin-bound polyamide reacting with an
active ester in solution, as per Dervan’s original recommendations (28). Application of dimer
building blocks are indicated by parentheses in polyamide syntheses, as for FH1024: TMG(PyIm)-β-Im-γ-(Py-β)-(PyPy)-β-PAM resin. For example, (PyPy) indicates that the pyrrolepyrrole dimer was used. When unavailable commercially, dimer building blocks were made by
standard methods as previously described (20). The final products were purified by reverse-phase
HPLC and characterized with NMR and HR mass spectrometry. The TMG substituted PAs were
synthesized by virtually identical solid phase methods up to the pyrrole group (4-amino-Nmethylpyrrole-2-carboxyamide). To generate the final building block where TMG is connected to
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the H2N-Py moiety, HATU (29) has been used (30). The PA concentration was determined by
accurate weighting on a five place analytical balance and dissolving the compound in an
appropriate volume of solvent.
KA2034: HRMS calc’d for C56H71N21O11 1213.56452, found 1213.5574
1

H NMR (600 MHz, DMSO-d6) δ = 10.37 (s, 1 H), 10.35 (s, 1 H), 10.05 (d, J = 1.2 Hz, 1

H), 9.93 (s, 1 H), 9.89 (s, 1 H), 9.89 (s, 1 H), 9.82 (s, 1 H), 9.31 (br. s., 1 H), 8.10 (d, J = 1.8 Hz,
1 H), 8.05 (t, J = 5.9 Hz, 1 H), 8.02 (t, J = 5.7 Hz, 1 H), 7.97 (t, J = 6.2 Hz, 1 H), 7.88 (t, J = 6.2
Hz, 1 H), 7.50 (s, 1 H), 7.40 (s, 1 H), 7.28 (d, J = 1.8 Hz, 1 H), 7.25 - 7.21 (m, 2 H), 7.17 (d, J =
1.8 Hz, 1 H), 7.15 (d, J = 1.8 Hz, 1 H), 7.09 - 7.05 (m, 2 H), 6.98 (d, J = 2.1 Hz, 1 H), 6.88 (d, J =
1.8 Hz, 1 H), 6.87 (d, J = 1.8 Hz, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.83
(s, 3 H), 3.83 (s, 3 H), 3.81 (s, 3 H), 3.52 (q, J = 6.7 Hz, 2 H), 3.42 - 3.35 (m, 2 H), 3.27 (q, J = 6.6
Hz, 2 H), 3.12 (q, J = 6.5 Hz, 2 H), 3.04 - 2.97 (m, 2 H), 2.75 (d, J = 5.0 Hz, 6 H), 2.60 (t, J = 6.5
Hz, 2 H), 2.35 (t, J = 7.2 Hz, 2 H), 2.27 (t, J = 7.5 Hz, 2 H), 1.83 - 1.77 (m, 2 H), 1.77 - 1.70 (m,
2 H)
C NMR (151 MHz, DMSO-d6) δ = 172.5, 171.0, 169.0, 168.5, 161.2, 158.6, 158.5, 158.5,
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158.4, 158.0, 157.9, 157.8, 136.1, 135.8, 134.0, 133.6, 122.8, 122.7, 122.7, 122.7, 122.2, 122.2,
122.1, 122.0, 122.0, 120.7, 119.3, 118.5, 118.4, 118.1, 117.9, 114.3, 113.6, 106.9, 104.8, 104.7,
104.3, 103.9, 54.7, 42.3, 40.0, 38.1, 36.2, 36.0, 35.9, 35.6, 35.4, 34.9, 34.9, 34.7, 33.1, 25.6, 24.5
KA2035: HRMS calc’d for C59H72N22O11 1264.57542, found 1264.5696
1

H NMR (600 MHz, DMSO-d6) δ = 10.31 (s, 1 H), 10.26 (s, 1 H), 10.07 (s, 1 H), 9.93 (s,

1 H), 9.90 (s, 2 H), 9.89 (s, 1 H), 9.84 (s, 1 H), 9.24 (br. s., 1 H), 8.12 (d, J = 1.8 Hz, 1 H), 8.07 7.99 (m, 4 H), 7.55 (s, 1 H), 7.50 (s, 1 H), 7.39 (d, J = 1.8 Hz, 1 H), 7.28 (d, J = 1.8 Hz, 1 H), 7.22
(d, J = 1.8 Hz, 1 H), 7.22 (d, J = 1.8 Hz, 1 H), 7.17 - 7.15 (m, 2 H), 7.15 (d, J = 1.8 Hz, 1 H), 7.07

24

(s, 2 H), 7.00 (d, J = 1.8 Hz, 1 H), 6.88 (d, J = 1.2 Hz, 2 H), 3.98 (s, 3 H), 3.94 (s, 3 H), 3.87 (s, 3
H), 3.85 (s, 3 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.83 (s, 3 H), 3.80 (s, 3 H), 3.42 - 3.35 (m, 2 H), 3.30
(q, J = 6.8 Hz, 2 H), 3.12 (q, J = 6.5 Hz, 2 H), 3.03 - 2.97 (m, 2 H), 2.75 (d, J = 4.7 Hz, 6 H), 2.35
(t, J = 7.3 Hz, 2 H), 2.28 (t, J = 7.6 Hz, 2 H), 1.85 - 1.78 (m, J = 7.1, 7.1, 14.5 Hz, 2 H), 1.78 1.71 (m, 2 H)
C NMR (151 MHz, DMSO-d6) δ = 171.0, 169.0, 161.2, 158.7, 158.6, 158.6, 158.5, 158.1,
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157.9, 155.7, 136.1, 135.9, 134.1, 134.1, 134.0, 122.8, 122.7, 122.7, 122.7, 122.2, 122.2, 122.1,
122.0, 122.0, 121.2, 120.8, 119.3, 118.5, 118.1, 117.9, 114.7, 114.3, 105.5, 104.8, 104.8, 104.3,
104.0, 54.7, 42.3, 40.4, 40.0, 38.0, 36.3, 36.2, 36.1, 35.9, 35.6, 35.4, 34.9, 34.9, 33.1, 25.6, 24.5
EA calc’d for C59H72N22O11(3CF3CO2H)(9H2O): C, 44.12%; H, 5.30%; N, 17.41%.
Found: C, 43.87; H, 4.92%; N, 17.13%.
KA2040: HRMS: calc’d for C53H70N20O11 1162.55362, found 1162.5466
1

H NMR (600 MHz, DMSO-d6) δ = 10.37 (s, 1 H), 10.35 (s, 1 H), 10.05 (s, 1 H), 9.88 (s,

1 H), 9.84 (s, 1 H), 9.75 (s, 1 H), 9.25 (br. s., 1 H), 8.10 (d, J = 1.5 Hz, 1 H), 8.07 - 8.03 (m, 2 H),
8.02 (t, J = 5.7 Hz, 1 H), 7.96 (t, J = 6.0 Hz, 1 H), 7.89 (t, J = 6.0 Hz, 1 H), 7.50 (s, 1 H), 7.39 (s,
1 H), 7.28 (d, J = 1.8 Hz, 1 H), 7.16 (d, J = 1.8 Hz, 1 H), 7.15 (d, J = 1.8 Hz, 1 H), 7.09 (d, J = 1.8
Hz, 1 H), 6.98 (d, J = 2.1 Hz, 1 H), 6.86 (d, J = 1.8 Hz, 1 H), 6.85 (d, J = 1.8 Hz, 1 H), 6.63 (d, J
= 1.5 Hz, 1 H), 3.94 (s, 3 H), 3.90 (s, 3 H), 3.83 (s, 3 H), 3.82 (s, 3 H), 3.80 (s, 3 H), 3.77 (s, 3 H),
3.55 - 3.49 (m, 2 H), 3.45 - 3.40 (m, 2 H), 3.40 - 3.35 (m, 2 H), 3.28 - 3.22 (m, 2 H), 3.14 - 3.08
(m, 2 H), 3.04 - 2.97 (m, 2 H), 2.74 (d, J = 5.0 Hz, 6 H), 2.60 (t, J = 6.6 Hz, 2 H), 2.52 - 2.47 (m,
2 H), 2.35 (t, J = 7.2 Hz, 2 H), 2.24 (t, J = 7.5 Hz, 2 H), 1.81 - 1.70 (m, 4 H)
C NMR (151 MHz, DMSO-d6) δ = 171.0, 169.0, 168.5, 167.8, 162.7, 161.2, 161.2, 158.6,
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158.5, 158.4, 158.4, 158.1, 157.9, 136.1, 135.8, 133.9, 133.6, 122.7, 122.7, 122.7, 122.0, 122.0,
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121.9, 120.7, 119.3, 118.1, 117.9, 117.6, 117.2, 114.3, 113.5, 104.8, 104.3, 104.0, 103.4, 54.7,
42.3, 40.0, 38.1, 36.2, 36.0, 35.9, 35.9, 35.8, 35.6, 35.5, 35.4, 34.9, 34.9, 34.7, 33.1, 25.5, 24.5
EA calc’d for C53H70N20O11(3CF3CO2H)(6H2O): C, 43.92%; H, 5.31%. Found: C, 44.15;
H, 4.95%.
KA2041: HRMS: calc’d for C53H70N20O11 1162.55362, found 1162.5466
1

H NMR (600 MHz, DMSO-d6) δ = 10.31 (s, 1 H), 10.26 (s, 1 H), 10.07 (d, J = 0.9 Hz, 1

H), 9.90 (s, 1 H), 9.88 (s, 1 H), 9.84 (s, 1 H), 9.77 (s, 1 H), 9.26 (br. s., 1 H), 8.12 (d, J = 1.8 Hz,
1 H), 8.08 - 7.99 (m, 4 H), 7.55 (s, 1 H), 7.49 (s, 1 H), 7.39 (d, J = 1.5 Hz, 1 H), 7.28 (d, J = 1.8
Hz, 1 H), 7.16 (d, J = 1.8 Hz, 1 H), 7.15 (d, J = 1.8 Hz, 1 H), 7.14 (d, J = 1.8 Hz, 1 H), 7.10 (d, J
= 1.8 Hz, 1 H), 7.00 (d, J = 1.8 Hz, 1 H), 6.86 (d, J = 1.8 Hz, 1 H), 6.85 (d, J = 2.1 Hz, 1 H), 6.64
(d, J = 1.8 Hz, 1 H), 3.98 (s, 3 H), 3.93 (s, 3 H), 3.87 (s, 3 H), 3.85 (s, 3 H), 3.81 (s, 3 H), 3.79 (s,
3 H), 3.78 (s, 3 H), 3.45 - 3.40 (m, 2 H), 3.40 - 3.35 (m, 2 H), 3.28 (q, J = 6.7 Hz, 2 H), 3.11 (q, J
= 6.5 Hz, 2 H), 3.03 - 2.98 (m, 2 H), 2.74 (d, J = 5.0 Hz, 6 H), 2.51 - 2.48 (m, 2 H), 2.35 (t, J = 7.2
Hz, 2 H), 2.25 (t, J = 7.5 Hz, 2 H), 1.79 (td, J = 7.3, 14.5 Hz, 2 H), 1.76 - 1.71 (m, 2 H)
C NMR (151 MHz, DMSO-d6) δ = 174.1, 172.1, 170.9, 164.4, 164.3, 161.8, 161.7, 161.7,
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161.5, 161.3, 161.1, 161.0, 160.9, 158.9, 139.2, 139.1, 137.2, 137.2, 125.9, 125.8, 125.3, 125.2,
125.2, 125.0, 125.0, 124.3, 124.0, 122.5, 121.3, 121.1, 120.7, 120.1, 117.9, 117.4, 108.6, 107.9,
107.4, 107.1, 106.5, 57.8, 45.4, 43.2, 41.2, 39.4, 39.4, 39.2, 39.1, 39.0, 38.7, 38.6, 38.5, 38.0, 38.0,
36.2, 28.7, 27.6
KA2114: HRMS: calc’d for C58H76N22O11 1256.6064, found 1256.6028
1

H NMR (600 MHz, DMSO-d6) δ = 10.31 (s, 1 H), 10.26 (s, 1 H), 10.09 (s, 1 H), 9.90 (s,

1 H), 9.85 (s, 2 H), 9.83 (s, 1 H), 9.68 - 9.60 (m, 1 H), 8.12 (d, J = 1.2 Hz, 1 H), 8.10 - 8.00 (m, 5
H), 7.89 (br. s., 4 H), 7.55 (s, 1 H), 7.50 (s, 1 H), 7.39 (d, J = 1.2 Hz, 1 H), 7.29 (d, J = 1.8 Hz, 1
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H), 7.17 (d, J = 1.2 Hz, 1 H), 7.15 (d, J = 1.8 Hz, 2 H), 7.10 (d, J = 1.8 Hz, 1 H), 7.00 (d, J = 1.8
Hz, 1 H), 6.85 (d, J = 1.2 Hz, 1 H), 6.84 (d, J = 1.2 Hz, 1 H), 6.67 (d, J = 1.8 Hz, 1 H), 3.98 (s, 3
H), 3.94 (s, 3 H), 3.87 (s, 3 H), 3.85 (s, 3 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.77 (s, 3 H), 3.46 - 3.39
(m, 2 H), 3.39 - 3.33 (m, 2 H), 3.29 (q, J = 6.7 Hz, 2 H), 3.21 - 3.14 (m, 1 H), 3.14 - 3.09 (m, 2 H),
3.09 - 2.95 (m, 3 H), 2.91 - 2.82 (m, 2 H), 2.73 (d, J = 4.7 Hz, 3 H), 2.53 - 2.46 (m, 2 H), 2.34 (t,
J = 7.0 Hz, 2 H), 2.28 (t, J = 7.3 Hz, 2 H), 1.96 - 1.86 (m, 2 H), 1.84 - 1.72 (m, 4 H)
C NMR (151 MHz, DMSO-d6) δ = 174.1, 172.2, 170.9, 165.8, 164.4, 164.3, 161.8, 161.7,
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161.7, 161.7, 161.5, 161.4, 161.2, 161.0, 161.0, 158.9, 139.2, 139.1, 137.2, 137.2, 125.9, 125.9,
125.8, 125.3, 125.2, 125.2, 125.1, 125.0, 124.4, 124.0, 122.5, 121.2, 121.1, 120.8, 120.5, 118.6,
117.9, 117.4, 108.6, 107.9, 107.3, 107.0, 106.7, 56.4, 55.2, 43.2, 41.2, 39.4, 39.4, 39.3, 39.2, 39.1,
38.9, 38.7, 38.7, 38.6, 38.5, 38.0, 38.0, 36.3, 28.8, 27.1, 24.9
EA calc’d for C58H76N22O11(4CF3CO2H)(7H2O): C, 43.09%; H, 5.15%; N, 16.75%;.
Found: C, 43.10; H, 4.77%; N, 16.07%
KA2115: HRMS: Calc’d for C55H75N21O11 1205.5954, found 1205.5932
1

H NMR (600 MHz, DMSO-d6) δ = 10.37 (s, 1 H), 10.35 (s, 1 H), 10.06 (s, 1 H), 9.85 (s,

1 H), 9.84 (s, 1 H), 9.81 (s, 1 H), 9.71 - 9.60 (m, 1 H), 8.11 (d, J = 1.2 Hz, 1 H), 8.08 (t, J = 5.9
Hz, 1 H), 8.06 - 8.00 (m, 2 H), 7.97 (t, J = 5.9 Hz, 1 H), 7.93 - 7.82 (m, 5 H), 7.50 (s, 1 H), 7.40
(s, 1 H), 7.28 (d, J = 1.8 Hz, 1 H), 7.17 (d, J = 1.8 Hz, 1 H), 7.14 (d, J = 1.2 Hz, 1 H), 7.11 (d, J =
1.8 Hz, 1 H), 6.98 (d, J = 1.8 Hz, 1 H), 6.85 (d, J = 1.8 Hz, 1 H), 6.84 (d, J = 1.2 Hz, 1 H), 6.67
(d, J = 1.8 Hz, 1 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.83 (s, 3 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.78 (s,
3 H), 3.52 (q, J = 6.5 Hz, 2 H), 3.47 - 3.40 (m, 2 H), 3.40 - 3.32 (m, 2 H), 3.27 (q, J = 6.8 Hz, 2
H), 3.22 - 3.15 (m, 1 H), 3.15 - 3.09 (m, 2 H), 3.09 - 2.96 (m, 3 H), 2.92 - 2.82 (m, J = 5.9 Hz, 2
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H), 2.73 (d, J = 4.7 Hz, 3 H), 2.60 (t, J = 6.5 Hz, 2 H), 2.53 - 2.46 (m, 2 H), 2.34 (t, J = 7.3 Hz, 2
H), 2.26 (t, J = 7.3 Hz, 2 H), 1.96 - 1.85 (m, 2 H), 1.83 - 1.73 (m, 4 H)
C NMR (151 MHz, DMSO-d6) δ = 171.0, 169.1, 168.6, 167.8, 162.7, 161.3, 161.2, 158.7,
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158.6, 158.5, 158.4, 158.4, 158.4, 158.2, 158.0, 157.9, 136.1, 135.8, 134.0, 133.6, 122.8, 122.8,
122.7, 122.1, 122.0, 122.0, 121.9, 121.1, 120.8, 119.4, 119.1, 118.8, 118.1, 117.9, 117.6, 116.9,
115.0, 114.4, 113.6, 113.0, 104.8, 104.2, 103.9, 103.6, 53.3, 52.1, 40.0, 38.1, 36.3, 36.3, 36.2, 36.0,
35.9, 35.8, 35.6, 35.6, 35.5, 35.4, 34.9, 34.9, 34.7, 33.1, 25.6, 24.0, 21.8
EA calc’d for C55H75N21O11(5CF3CO2H)(6H2O): C, 41.43%; H, 4.92%; N, 15.61%; F,
15.12%. Found: C, 41.51; H, 4.48%; N, 15.34%; F, 14.40%.
FH1024 1H NMR (500 MHz, DMSO-d6) δ =10.46(s, 1 H), 10.37(s, 1 H), 9.87(s, 1 H),
9.85(s, 1 H), 9.76(s, 1 H), 9.67(s, 1 H), 9.44(br. s, 1 H), 8.09~8.02(m, 3 H), 7.96(t, J=5.84Hz, 1
H), 7.84(s, 1 H), 7.81(t, J=5.85Hz, 3 H), 7.52(s, 1 H), 7.38(s, 1 H), 7.16(d, J=1.8Hz, 1 H), 7.15(d,
J=1.8Hz, 1 H), 7.09(d, J=1.8Hz, 1 H), 6.90(d, J=1.8Hz, 1 H), 6.87(d, J=1.8Hz, 1 H), 6.81(d,
J=1.8Hz, 1 H), 6.63(d, J=1.8Hz, 1 H), 3.94(s, 3 H), 3.9(s, 3 H), 3.87(s, 3 H), 3.81(s, 3 H), 3.79(s,
3 H), 3.77(s, 3 H), 3.53(q, J=6.01Hz, 2 H), 3.4(m, 4 H), 3.25(q, J=6.28Hz, 2 H), 3.14(m, 4 H),
3.04(m, 4 H), 2.91-2.87(m, 12 H), 2.74(d, J=5.03Hz, 4 H), 2.64(m, 1 H), 2.6(t, J=6.28Hz, 2 H),
2.36(t, J=7.2Hz, 3 H), 2.24(t, J=7.14Hz, 2 H), 1.9(m, 2 H), 1.71(m, 4 H)
FH1026 1H NMR (500 MHz, DMSO-d6) δ =10.46(s, 1 H), 10.25(s, 1 H), 9.88(s, 1 H),
9.84(s, 1 H), 9.79(s, 1 H), 9.77(s, 1 H), 9.70(s, 1 H), 9.46(br. s, 1 H), 8.09~8.0(m, 4 H), 7.83(d, 4
H), 7.57(s, 1 H), 7.49(s, 1 H), 7.37(d, J=1.53Hz, 1 H), 7.19(d, J=1.53Hz, 1 H), 7.15(d, J=1.53Hz,
1 H), 7.10(d, J=1.53Hz, 1 H), 6.92(d, J=1.68Hz, 1 H), 6.86(d, J=1.53Hz, 1 H), 6.83(d, J=1.53Hz,
1 H), 6.63(d, J=1.53Hz, 1 H), 3.99(s, 3 H), 3.96(s, 3 H), 3.93(s, 3 H), 3.89(s, 3 H), 3.82(s, 3 H),
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3.80(s, 3 H), 3.78(s, 3 H), 3.44~3.26(m, 8 H), 3.173~3.00(m, 12 H), 2.99-2.87(m, 4 H), 2.74(d,
J=4.9Hz, 4 H), 2.63(m, 1 H), 2.36(m, 3 H), 2.25(t, J=7.64Hz, 2 H), 1.91(m, 4 H), 1.71(m, 4 H)
FH1028 1H NMR (500 MHz, DMSO-d6) δ =10.46(s, 1 H), 10.37s, 1 H), 9.92(s, 1 H),
9.88(s, 1 H), 9.82(s, 1 H), 9.67(s, 1 H), 9.44(br. s, 1 H), 8.09 (t, J=5.76Hz, 1 H), 8.04 (t, J=5.76Hz,
1 H), 8.00 (t, J=5.76Hz, 1 H), 7.81(m, 4 H), 7.52(s, 1 H), 7.39(s, 1 H), 7.21(d, J=1.8Hz, 1 H),
7.20(d, J=1.8Hz, 1 H), 7.19(d, J=1.8Hz, 2 H), 7.09(d, J=1.8Hz, 1 H), 6.91(d, J=1.8Hz, 1 H), 6.87(d,
J=1.8Hz, 1 H), 6.81(d, J=1.8Hz, 1 H), 3.93(s, 3 H), 3.91(s, 3 H), 3.87(s, 3 H), 3.86(s, 3 H), 3.85(s,
3 H), 3.83(s, 3 H), 3.81(s, 3 H),

3.53(q, J=6.32Hz, 2 H), 3.38 (q, J=6.92Hz, 2 H), 3.27(q,

J=6.62Hz, 2 H), 3.15~3.01(m, 8 H), 2.99-2.87(m, 10 H), 2.74(d, J= 4.9Hz, 4 H), 2.63(m, 1 H),
2.59(t, J=6.62Hz, 2 H), 2.36(t, J=7.23Hz, 3 H), 2.25(t, J=7.53Hz, 2 H), 1.91(m, 4 H), 1.71(m, 4 H)
KJK6162 1H NMR (300 MHz, DMSO-d6) δ =10.50(s, 1 H), 10.34(s, 1 H), 9.94(m, 2H),
9.89(m, 2 H), 9.70(s, 1 H), 8.74(d, J=4.56Hz, 2 H), 8.51(d, J=8.45Hz, 2 H), 8.12(s, 1 H), 7.56(s, 1
H), 7.50(q, J=4.42Hz, 4 H), 7.38(d, J=1.38Hz, 1 H), 7.23(d, J=1.83Hz, 1 H), 7.17(d, J=6.89Hz, 2
H), 7.11(d, J=1.8Hz, 1 H), 7.04(d, J=1.83Hz, 1 H), 6.91(d, J=1.54Hz, 1 H), 6.86(d, J=1.97Hz,
J=4.09Hz, 2 H), 6.80(t, J=1.97Hz, 1 H), 6.59(s, 1 H), 5.75(s, 5 H), 4.19(q, J=5.45Hz, 3H), 3.98(s,
3H), 3.93(s, 3 H), 3.87(s, 3 H), 3.86(s, 3 H), 3.84(s, 3 H), 3.82(s, 3 H), 3.81(s, 3 H), 3.79(s, 3 H),
3.67(s , 2 H), 3.60(s , 4 H), 3.17(s, 6 H), 3.15(s, 6 H), 3.08(t, J=0.73 Hz, 1 H), 2.88(t, J=1.90Hz,
1 H), 2.68(s, 2H), 2.08(s, 2H), 1.22( m, 2 H), 1.16(t, J=7.38Hz, 2 H)
2.3.2

Biophysical methods

Surface Plasmon Resonance (SPR) SPR measurements were performed using Biacore
T200 optical biosensor systems (GE Healthcare, Inc., Piscataway, NJ). Filtered and degassed
HEPES buffer (10 mM HEPES, 400 mM NaCl, 1 mM EDTA and 0.05% v/v surfactant P20, pH
7.4) was used in SPR experiments. The measurement process is the same as described previously
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(21). A biotinylated hairpin DNA (5’-biotin-CCAAATAAAAGGAAGTGAAACCAAGCTCT
CTTGGTTTCACTTCCTTTTATTT GG, Fig.2.1) was immobilized on the surface of a sensor chip
pre-coated with streptavidin. A reference channel was prepared without DNA immobilization for
baseline correction. To form the PA-DNA complex, an increasing concentration of PA was
injected onto the chip surface at a flow rate of 100 µL/min for 210 seconds until a steady state was
reached. This high flow rate was used to minimize mass transfer effects. The association was
followed by a pure running buffer flow at the same rate, causing the complex to dissociate. At the
end of each cycle, 1 M NaCl was used as regeneration solution and injected over the surface to
completely wash off the residual PA and prepare the surface for the next cycle.
The kinetic analyses were performed using standard 1:1 global fitting model with mass
transport parameters incorporated as described previously (31, 32). The equilibrium constant of
some compounds were determined using a steady state fit, because the kinetic parameters went
beyond the detection limit and were too fast to determine. This often features the weak binding
compounds.
Thermal Melting (Tm) Thermal melting studies were conducted on a Cary 300 Bio
UV/visible spectrophotometer (Varian) in filtered buffer containing 10 mM HEPES (pH 7.4), 50
mM NaCl and 1 mM EDTA. Samples were heated at a rate of 0.5 °C/min, and the corresponding
absorbance at 260 nm was recorded and plotted against the temperature. The Tm of DNA was
measured at 3 μM, and an equivalent amount of PA was added to obtain the Tm of PA-DNA
complex. The difference between the Tm of DNA in the absence and presence of PA is thus a ∆Tm.
Circular Dichroism Spectroscopy (CD) CD spectra were obtained using a Jasco J-810
spectrometer (Jasco Inc., Easton, MD) with a scan range from 400 nm to 230 nm at 25 °C. The
spectra were averaged over four scans with a scan speed of 50 nm·min-1 and a buffer blank
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correction. A 5µM DNA solution was firstly scanned and the PAs were then titrated into the same
cuvette at increasing concentration ratios. The complex was scanned under the same condition. A
hairpin DNA without a biotin label (5’-GGAAGTGAACCTCTGTTCACTTCC-3’) was used and
the experimental buffer is the same as that used in thermal melting study.
2.4

Results
2.4.1

Quantitative evaluation of PA-DNA binding kinetics and affinity

β-inserts Biosensor-Surface Plasmon Resonance (SPR) is a label-free technique with
excellent sensitivity that can quantitatively monitor biomolecular binding interactions in real time.
Representative SPR sensorgrams are shown in Fig 2.2. It is noticeable that the dissociation rate is
getting faster from strong to weak binders. The other sensorgrams are listed in Fig. 2.3. The kinetic
rate constants and equilibrium binding affinities of eleven designed PAs were determined using
SPR and summarized in Table 2.1. The six PAs in the β-insert group have a formamido (F) group
at the N-terminus and β at different positions. KA2115, with two βs replacing Py rings at positions
3 and 7, leads the group with the highest binding affinity (0.49 ± 0.01 nM). KA2040, another PA
with two βs but at rings 3 and 6, binds to the cognate sequence essentially equally as strong (0.54
± 0.01 nM). A single β inserted PA at ring 3, KA2034, displayed a slightly weaker but quite
comparable binding affinity (0.67 ± 0.01 nM) to KA2115 and KA2040. These results suggest that
the position and number of β inserts in the lower strand (rings 5-8) is not a dominant factor for this
hairpin PA-DNA interaction, and do not contribute significantly to binding affinity enhancement.
The unmodified parent molecule, KA2035, exhibits a moderate affinity (1.30 ± 0.01 nM) with
regard to the last three molecules. This is primarily caused by its relatively lower association rate
(ka). KA2035, however, has the second lowest dissociation rate (kd) among all the PAs tested,
which compensated for its low ka and rendered KA2035 a relatively strong binder. KA2041, with

31

only one β-alanine at position 6, binds the cognate DNA with a higher ka but a much higher kd
compared to KA2035, resulting in weakened overall interactions. Nonetheless, this situation
worsened when the replacement was moved to position 7, as in KA2114. The kd of KA2114 is so
high, around 20 times higher than the parent molecule KA2035, that it cannot obtain high binding
affinity even with a higher ka value than KA2035.
Cationic substitutions Relative to the β insertion group, in which all molecules conserve
an unmodified N-terminus, four PAs were designed with further modification at the N-terminus
with the specific cationic substituent, tetramethylguanidinyl (TMG). The binding affinities and
kinetics of these PAs have been evaluated (Table 2.1). FH1028, the PA with a single β insert at
ring 3 and a TMG at the N-terminus leads all the other PAs in binding affinity to the cognate DNA
(0.16 ± 0.02 nM). The high affinity is attributed to its high ka and relatively low kd. Compared to
its analog KA2034 which has the identical β modification but different N-terminal substituents,
FH1028 has a five-fold higher ka which contributes to the strengthened binding affinity. This result
indicates that the TMG group can accelerate PA-DNA binding. Similarly, FH1024 (N-TMG) and
KA2040 (N-F) were compared to each other because they have identical β-inserts at positions 3
and 6. The N-TMG attached FH1024 has a ka that is around two times higher than KA2040 (N-F),
but its drastically increased kd makes it non-competitive with KA2040. Interestingly, KJK6162,
modified directly from the parent, KA2035, by substituting F with TMG at the N-terminus, binds
the λB sequence so weakly (60 times weaker than KA2035) that its kinetic rate constant cannot be
determined. Similarly, FH1026, the N-TMG analog of KA2041, has a 20 times weaker binding
affinity than KA2041, well out-of-range kinetic constants by SPR.
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2.4.2

Screening of relative binding affinities with cognate and mutant DNAs by

Thermal Melting (Tm)
Thermal melting is an effective way to evaluate the relative binding affinity and the
selectivity of a particular PA among several DNA sequences. Tm of the cognate DNA and DNA
mutants and their complexes with PAs are determined at 1:1 molar ratio. The difference between
Tm values of the complex and DNA, ΔTm, reflects the thermal stability of the complex, thus the
binding affinity of PA. The values are listed in Table 2.2.
The comparison of mutant DNAs are made with each PA-cognate DNA complex and are
categorized according to their extent of binding. ΔTm values in ±5% relative to the ΔTm of cognate
DNA are designated as equal and uncolored, dark gray means slightly stronger (≤120%, >105%),
gray means slightly weaker (<95%, ≥80%), light gray is categorized as weaker (<80%, ≥50%)
and lightest gray is much weaker (<50%). The determined ΔTm values of PAs with cognate DNA
are in good agreement with the SPR results.
The first mutant sequence evaluated is a Py recognizing T that is mutated to A. Both in βinsert and the cationic substituent group, the affinity is not affected significantly and is either equal
or slightly higher or lower, even for the molecules where Py is replaced by β (single-β or doubleβ replacement). Particularly, KA2034 (f-PyImβIm-γ-PyPyPyPy-β-Dp) showed slightly weaker
binding when β/Py targeting T·A is switched to A·T. In a similar case, KA2041 (f-PyImPyIm-γPyβPyPy-β-Dp) who has Py/β targeting T·A exhibited slightly higher affinity to the A·T mutant.
These results indicate that T·A prefers β/Py to Py/β, and vice versa. The second mutant is made
by switching the terminal amine recognizing A to T. In both groups, most molecules are not
affected by this change and the binding affinity stays comparable to that of the cognate DNA.
What is interesting is, KA2040 and FH1024, both of which have double-β replacement where
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Py/Py is substituted by β/β, have slightly elevated binding affinities. The third mutant is considered
as a more dramatic mutation, in which the Im recognizing G is mutated to T. As a result, an
apparent drop of binding affinity is observed for most PAs. However, as a strong binder to cognate
DNA, FH1028 and KA2115 still binds to mutant 3 quite strongly, ΔTm = 14.8, and 10.5,
respectively. Interestingly, the binding of KA2041 and KA2114 to mutant 3 is comparable to that
of cognate DNA, especially KA2114. This result indicates that even though Im recognizes G
specifically, it can still tolerate T to some extent, so that the complex can still be formed. Mutants
4 and 5 are made by switching G to C. Much weaker binding appeared at this level of mutation.
Since in this case, Py is designated to target G, which is known with either one-β or two-β
replacement, the Im/Py or Im/β combination is not very tolerant with C·G base pairs.
2.4.3

Effect of N-terminal cationic group on PA selectivity of DNA flanking

sequences
To further evaluate the effect of the N-terminal cationic group on PA-DNA interactions,
binding affinities of the same set of PAs to DNAs that have different mutated flanking sequences
were measured and compared. The three DNAs used here are λB DNA (5’-BiotinCCAAATAAAAGGAAGTGAAACCAAGCTCTCTTGGTTTCACTT CCTTTTATTTGG-3’),
SC1 DNA (5’-Biotin-CGGCCAAGCCGGAAGTGAGTGCCTCTCGGCACTCACTTCCGGC
TTGGCCG-3’), and GAGA mutant DNA (5’-Biotin-CCAAATAAAAGAGAGTGAAACC
AAGCTCTCTTGGTTTCACTCTCTTTTATTTGG-3’). In λB DNA, the PA binding site AGTGA- is surrounded by A on both 5’ and 3’ ends. The SC1 sequence has a G flanking at the 3’
side, while GAGA sequence has a G at the 5’ end. The binding to the DNAs was evaluated by SPR
as described above and the SPR sensorgrams and binding results are shown in Fig. 2.4, Fig. 2.5
and Table 2.3. By comparing binding of λB and SC1 DNA, the N-F molecules (KA2035 plus β-

34

inserts group) have very similar binding affinities to both sequences. For the N-TMG molecules,
the binding affinities to λB DNA are fairly strong. However, when tested against the SC1 DNA,
their binding affinities significantly decreased, even to the point of no detectable binding.
Interestingly, when we compare the binding to GAGA sequence with λB DNA, the N-TMG group
of PAs show strong and comparable binding in general, and binding of FH1024 is even stronger
to GAGA than λB DNA. Fig. 2.6B shows the binding affinity of PAs to λB, SC1 and GAGA
mutant sequences. It is clear that each PA in the β-inserts group has very close binding strength
to all three DNAs, except that KA2115 has a slightly larger deviation. But in the cationic
substitution group, hardly any traces of PA-SC1 binding (black column) can be seen. These results
suggest that N-TMG PAs are quite sensitive and selective to the 3’ flanking base pairs of -AGTGA, but not 5’, and they prefer A to G.
2.4.4

Evaluation of the PA binding mode by CD

In Figure 2.7, the large positively induced CD signals upon PA-DNA binding at around
300 nm to 370 nm, where PAs absorb while DNA signals do not interfere indicate a DNA minor
groove binding mode as expected for hairpin PAs (33).
2.5

Discussion
2.5.1

Quantitative evaluation of PA-DNA binding kinetics and affinity

SPR has greatly facilitated the quantification of kinetics between small molecules and
DNA. As important, sequence-specific DNA minor groove binders, polyamides have been
extensively studied over the decades and are seen as potential drug targets for antiviral, antitumor
and antibacterial therapeutics. Yet the position and number dependence of β-modified PA-DNA
interaction still have many uncertainties and their features play a critical role in designing more
specific and stronger binding PAs.
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β-inserts As shown in Fig. 1B, along the λB sequence, the 5’ side of PU.1 binding site
is an AT rich region. Previous literature has employed the A·T specific minor groove targeting
compounds to bind to the 5’ side A·T base pairs in order to inhibit PU.1 binding (34). The efficient
allosteric inhibition activity demonstrated by these compounds has encouraged us to further extend
our target binding site to the 3’ side. A combination of 5’ side binding minor groove heterocyclic
cations and 3’ targeting PAs should provide a very powerful inhibition potential.
The parent PA, KA2035 was thus designed, according to the recognition rules, to target
the 3’ side AGTGA sequence. The PA has a strong binding affinity of 1.30 nM, and was able to
successfully and precisely recognize the target sequence. β-alanine is a building block that is
incorporated into PAs to increase their flexibility. In a successful effort to improve binding affinity,
KA2035 was modified by replacing internal Py at different positions with β inserts. The SPR
binding affinities of modified PAs vary in a β insert number-and-position dependent manner.
Specifically, when compared to KA2035, three PAs (KA2115, KA2040 and KA2034) have
strengthened binding affinities. A common modification strategy adopted by all the three PAs is
that Py heterocycle 3 is substituted by one β insert. It is highly likely that this position 3 β insert
in the upper strand (rings 1-4) added the flexibility needed to the molecule to adjust to the cognate
DNA minor groove curvature. However, this particular β also allows for relaxation and
realignment of the PA to compensate for the different positions of H-bond donors and acceptors
in Py and Im components of PAs, where Py uses an exocyclic amide NH as an H-bond donor to
DNA (for A, T and C) and Im uses a cyclic N as an H-bond acceptor from G. The H-bonding
locations on DNA are in register with each other, but those on the PA are not. Therefore, the
locations of hydrogen bond donors and acceptors between PA and DNA are better oriented at more
optimized distances and angles, resulting in strengthened hydrogen bonding with higher PA-DNA
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binding affinity. On the other hand, a single β insert on the lower strand (rings 5-8), KA2041 and
KA2114, gave no enhanced binding. This is due to the possibility that replacement of Py by a β at
position 6 or 7 does not help the PA overcome its overall rigidity. Instead, a reduction of van der
Waals contacts occurred when substituting Py 6 or 7 with a β. Interestingly, the β position in double
β-substituted KA2115 (KD = 0.49 nM) is a combination of βs in the single β-substituted KA2034
(KD = 0.67 nM) and KA2114 (KD = 4.1 nM), but the binding affinity of KA2115 is higher than
either of the other two. Very similarly, the double β-substituted KA2040 (KD = 0.54 nM) also has
higher binding affinities than the single β-substituted KA2034 (KD = 0.67 nM) and KA2041 (KD
= 1.62 nM). This is probably because that the combination of upper strand and lower strand β
inserts gives PA even better flexibility to arrange itself to the optimal orientation for hydrogen
bonding upon interacting with DNA, and because that optimal β-β stacking can occur when
binding to certain DNA sequence.
The binding affinity is determined by the association and dissociation rate constants. From
Table 2.1, it is clear that all PAs in the β-inserts group have higher association rate constants than
the parent PA, KA2035. This is in contrast to a previous study in which the association rate
constants of modified PAs were generally lower than those of unmodified compounds (20). Of
note, the 2014 study focused on the dImImPyIm-γ-PyPyPyPy-β-Dp/Ta sequence and derivatives
while the current work studies formamidoPyImPyIm-γ-PyPyPyPy-β-Dp/Ta and derivatives. The
extra, in register H-bond provided by the potentially rotatable formyl group coupled with the
disparate target sequences of the two studies and different minor groove widths may all contribute
to fundamentally different binding kinetics. The opposite effects of β-alanine inserts on the
association rate of these two (current and previous) sets of PAs indicate that changes in PA
composition (Py and Im heterocycles arrangement and content) and targeted, cognate DNA
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sequence respond differently to β inserts. After inserting β, the previous PAs were too flexible and
needed time to adjust themselves to DNA upon binding, while the current set of β-inserted PAs fit
better to the curvature of λB sequence than the parent molecule, resulting in more rapid binding.
The dissociation rate constants of those PAs with increased affinity are quite comparable
to the parent PA, KA2035. For these tighter-binding PAs, as mentioned above, the upper strand β
modification has greatly optimized hydrogen bond donor and acceptor orientations and thus
strengthened hydrogen bonding between PAs and DNA (KA2034). But for the weak binding
KA2041 and KA2114, their dissociation is so much faster that they can hardly maintain strong
binding. It is noticeable that the single lower strand β replacement resulted in higher dissociation
rate constant. Bashkin et al. built a docking model to compare a single-β-inserted PA2 (ImImβPyγ-PyImPyPy-β-Dp) with an all-ring eight-ring PA1 (ImImPyPy-γ-PyImPyPy-β-Dp), and found
that Py is more effectively stacked with both the adjacent PA strand and the DNA backbone than
β-alanine (19). Higher dissociation rate constants for some β derivatives might be a result of loss
of hydrophobic interactions.
Cationic substitutions Since DNA is highly negatively charged, adding positive charges
on PAs should help enhance the electrostatic interactions between the two. More charged groups
can also improve the solubility of PAs. Therefore, in addition to β inserts, additional cationic
groups are attached to the N-termini to facilitate PA-DNA binding. SPR results showed varied
effects of cationic substitutions on PA-DNA interactions.
As shown in Fig. 2.6A, FH1024 and FH1028, compared to KA2040 and KA2034, their
analogs with formamido N-termini (N-F), exhibited slightly different binding affinities. FH1024
binds about three times weaker than KA2040 and FH1028 binds around three times tighter than
KA2034. Interestingly, both TMG derivatives have higher association rate constants than their
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formamido analogs. The results implied that N-TMG can help promote PA-DNA binding by
adding extra charge-charge interactions. On the other hand, the binding affinities of N-TMG
KJK6162 and FH1026 dropped to dramatically low values for eight-ring PAs and cannot compete
with their N-F analogs. This is probably because when the formamido group is substituted by the
bulky TMG at the N-terminus while not having β inserts on the top strand, molecules like FH1026
and KJK6162 are not flexible enough to accommodate either the repulsive electronic interactions
or the steric hindrance between the two termini. As a result, the free molecules tend to be less
stacked, making it harder to form hairpin and conform ideally to the minor groove of cognate DNA
upon binding. Interestingly, unlike KA2040 or KA2115, the affinity of the double β-substituted
TMG compound FH1024 (KD = 1.65 nM) is between the two single-β-substituted FH1028 (KD =
0.16 nM) and FH1026 (KD = 35 nM). The much higher dissociation constants of FH1024 than
KA2040 plays an important role in lowering its binding affinity, indicating that the N-TMG can
affect optimal β-β stacking and that the extra flexibility does not always optimally orient the PA
upon binding to DNA, while the loss of hydrophobic interactions can overshadow the effort to
enhancing hydrogen bonding strength.
2.5.2

Effect of N-terminal cationic group on PA selectivity of DNA flanking

sequences
The selective properties of the cationic TMG group over the immediate flanking sequence
of DNA binding site can be utilized as an important tool for drug design. The binding of the βinsert group molecules to SC1 sequence are in good agreement with their binding to λB sequence,
meaning that β inserts have similar effects on the binding to both DNA sequences. However, the
selective impacts of TMG overshadowed the β-insert effects in the cationic group, making it a
determinant factor upon binding to SC1 sequence. For GAGA sequence, β modification did not
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significantly increase the affinity among formamido group PAs, yet a single β replacement at
position 3 (KA2034) still showed stronger binding than the parent PA, KA2035. Especially, both
KA2115 and KA2040 showed weaker binding to GAGA than to the other two sequences, while
the other molecules in the group have comparable affinities to all three sequences. The N-TMG
FH1024, on the other hand, is around 12 times more favorable to GAGA sequence than λB
sequence. The difference in binding strength of those molecules caused by alteration in flanking
sequences, together with the selectivity of the TMG group, indicates that the DNA context can
affect some PA-DNA binding, thus increasing the selectivity of those PAs. This provides a way to
target one specific transcription factor among a transcription factor family, for which all proteins
have consensus binding site with different flanking sequences for the different specific targets. A
larger DNA pool is required for further tests of this selectivity.
2.6

Conclusions
Taken together, a binding pattern has been developed that links the modification with

binding affinity compared to the parent PA, KA2035: 1) For single-β-containing PA, β/Py
increases binding affinity when targeting T·A; Py/β decreases binding affinity when targeting T·A.
Im/β decreases binding affinity when targeting G·C. 2) For double-β-containing PA, Imβ/βPy
increases binding affinity when targeting GT·CA. β/β can increase or decrease binding affinity
when targeting T·A. 3) When compared to the TMG-PA KJK6162, any β modification can
increase the binding affinity (in the above, a slash “/” separates pairs of PA building blocks from
opposite strands of the hairpin).
Overall, when Py between two Im is replaced by β, the binding affinity tends to go up,
while if β appears on a lower strand consisting of four Py, the binding affinity tends to go down.
Fortunately, a combination of the two positions can bring the affinity back to even higher levels.
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Sugiyama et al has shown that Im heterocycles are more planar than Py rings, which makes an Imderived molecule more rigid than a corresponding Py-polyamide, e.g. when binding to DNA (35).
This could partially account for the slow association rate of the unmodified parent PA, KA2035.
However, when we substitute the Py in the middle (number 3) with β, the whole molecule,
especially the upper strand, becomes more flexible and more able to adjust to the curvature of
DNA’s minor groove upon binding. The finding that replacing Py between two imidazoles with β
increases affinity is consistent with Turner et al. results, where PA10 (ImβImPyPyPy-γImPyPyPyβPyβ-Dp) had ca. five times stronger binding affinity to its cognate DNA than the non
β-inserted PA9 (ImPyImPyPyPy-γ-ImPyPyPyPyPyβ-Dp), and PA12 (ImβImPy-γ-ImβImPyβDp), with two ImXIm (X = β, Py) groups involved, is 100 times stronger than its unsubstituted
analog PA11 (ImPyImPy-γ-ImPyImPyβ-Dp) in binding to its cognate DNA (17). Similarly,
Dickinson et al. also showed an increase in affinity when substituting Py in PA1 (ImPyImPy-γPyPyPyPy-β-Dp) with β in PA2 (ImβImPy-D-PyPyPyPy-β-Dp, where D denotes diaminobutyric
acid) (36). Other studies also showed increased binding affinities of ImβIm to 5’-GCGC-3’
sequence than ImPyIm (37, 38).
As for the bottom strand, the curvature of four Py fits nicely with that of DNA with optimal
hydrogen bonding. Replacing Py with β on the other hand would reduce the van der Waals
interaction between PA and DNA without allowing the PA to form better hydrogen bonds. This is
also shown in Bashkin’s docking model (19). As a result, the overall binding is weaker than
unmodified PA. Interestingly, when two of the above modifications are combined, the positive
binding effects of the upper strand can reverse the negative binding effects of the lower strand,
especially when Py/Py is replaced by β/β.
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The N-terminal cationic group can have a positive effect on accelerating the association
process of PA and DNA. However, because of the bulky nature of TMG group, steric clash and
sometimes repulsive electrostatic interactions are generated upon binding to DNA, resulting in
impaired DNA binding affinity of PAs. Thus, the TMG group has to be carefully combined with
β-alanine inserts to achieve optimal PA-DNA binding strength.
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2.9

Tables and Figures

β-alanine inserts

Cationic substitutions

A

N
C

1

2

3

4

8

7

6

5

B

λB DNA

PA binding site

C
5’-biotin-CCAAAAGGAAGTGAAACCAAG T
GGTTTTCCTTCACTTTGGTTC T C

Figure 2.1 Systematically designed polyamides and DNA sequence.
A) Systematically designed polyamides that are categorized into two modified groups:
β-alanine inserts (red) and cationic substitutions (blue). The illustration above KA2035
is the simplified representative of KA2035. The open and closed circles stand for pyrrole
and imidazole, respectively. The diamond represents β-alanine. The numbering starting
from N-terminus to C-terminus applies to all PAs. B) The biotinylated cognate binding
sequence of the PAs: λB DNA. The predetermined PA binding site is highlighted in the
green frame.
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KD = 0.67 nM

KD = 1.62 nM

KD = 4.1 nM

Figure 2.2 Representative SPR sensorgrams of PAs binding to λB DNA.
From left to right, there are strong (KD = 0.67 nM), intermediate (KD = 1.62 nM), and
weak (KD = 4.1 nM), binders. The colored lines are experimental sensorgrams. The black
overlays are 1:1 global kinetic fits.

Figure 2.3 SPR sensorgrams of PAs binding to λB DNA.
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Table 2.1 Kinetic rate constants and equilibrium binding constants for all PAs.
PAs in the β-inserts group are ranked according to their binding affinities from strong to weak.
FH1026 and KJK6162 have very fast binding kinetics that are beyond the limitation of
instrument detection. Thus no binding kinetics is reported here (ND). The equilibrium binding
affinities were measured using steady state fitting. Note that KA2035 is included into β-inserts
group for ease of comparison. Diamond, open circle and close circle represent β-alanine,
pyrrole and imidazole respectively; Red diamond denotes β-alanine that replaced Py; F means
formamido group and TMG means tetramethylguanidinyl group. Dp is short for 3(dimethylamino)propylamine and Ta is short for 3,3’-diamino-N-methyldipropylamine.

KA2115
F
Ta

KA2040

FH1024
TMG

F
Ta

Dp

KA2034

FH1028
TMG

F
Ta

Dp

KA2035

KJK6162
TMG

F

Ta

Dp

KA2041

FH1026

F

KA2114
F
Ta

TMG
Ta

Dp
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Table 2.2 ΔTm values of PAs with cognate and five mutant sequences.
The error of the ΔTm values are within 5%, based on experimental reproducibility.
DNA

PA
Tm (°C) of free
DNA

Mutant 1

Mutant 2

Mutant 3

Mutant 4

Mutant 5

AGAGA

AGTGT

AGTTA

ACTGA

AGTCA

68.3

66.0

68.4

63.7

68.8

69.4

AGTGA

KA2115

14.3

14.9

13.6

10.5

5.9

4.4

KA2040

10.1

9.0

11.6

4.5

3.9

2.4

KA2034

9.8

9.2

9.4

6.8

6.5

6.0

KA2035

9.7

9.5

9.4

4.9

3.9

2.6

KA2041

9.7

10.5

9.7

7.9

5.0

4.9

KA2114

7.7

7.2

7.7

7.5

3.0

3.6

FH1028

18.6

18.5

19.1

14.8

12.9

12.6

FH1024

9.6

8.5

11.7

7.0

4.4

5.4

FH1026

7.7

6.7

8.0

4.0

2.6

4.2

KJK6162

5.7

6.3

4.6

3.9

3.6

3.6

Slightly
stronger

Equal

Slightly
weaker

Weaker

Much
weaker
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SC1 DNA

PA binding site

C
5’-biotin-CGGCCAAGCCGGAAGTGAGTGC T
GCCGGTTCGGCCTTCACTCACG T C
Figure 2.4 SPR sensorgrams of PAs binding to SC1 sequence.
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GAGA mutant

PA binding site

C
5’-biotin-CCAAAAGAGAGTGAAACCAAG T
GGTTTTCTCTCACTTTGGTTC T C

Figure 2.5 SPR sensorgrams of PAs binding to GAGA mutant sequence.
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Table 2.3 Equilibrium binding affinities of all PAs with DNAs that have mutated
flanking sequences.
No means no binding was detected between PA and the corresponding DNA. Errors for
these equilibrium constant values are standard errors for the fitting and are within 2%
for kinetic fitting, within 6% for steady state fitting.
λB (KD/nM)
AAGTGAA

SC1 (KD/nM)
AAGTGAG

GAGA (KD/nM)
GAGTGAA

0.49

0.27

1.67

0.54

0.68

1.82

0.67

0.83

0.66

1.30

0.91

1.36

1.62

2.70

2.80

4.10

7.70

7.20

0.16

18

0.51

1.65

No

0.14

35

No

43

79

277

75

KA2115

β-alanine
inserts

F
Ta

KA2040
F
Dp

KA2034
F
Dp

KA2035
F
Dp

KA2041
F
Dp

KA2114
F
Ta

FH1028

Cationic
substitution

TMG
Ta

FH1024
TMG
Ta

FH1026
TMG
Ta

KJK6162
TMG
Ta

A

B

Figure 2.6 A) Direct comparison of equilibrium affinities of all PAs binding to λB
sequence. B) Binding affinities of all PAs to λB, SC1 and GAGA mutant sequences.
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TMG-PIβI
Ta-PPPP

F-PIβI
Ta-PβPP

F-PIβI
Dp-PPβP

F-PIβI
Dp-PPPP

F-PIPI
Dp-PPPP

F-PIPI
Dp-PPβP

F-PIPI
Ta-PβPP

TMG-PIβI
Ta-PPβP

TMG-PIPI
Ta-PPβP

Figure 2.7 CD spectra of PA titration with short λB sequence.

TMG-PIPI
Ta-PPPP
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3.1

Abstract
DNA minor groove binding polyamides have been extensively developed to control

abnormal gene expression. Establishment of the novel, inherently fluorescent Hx-amides has
provided an alternative path for studying DNA binding in cells by direct observation of cell
localization. Because of the 2:1 antiparallel stacking homodimer binding mode of these molecules
to DNA, modification of Hx-amides to AzaHx-amides has successfully extended the DNA
recognition repertoire, from central CG (recognized by Hx-I) to central GC (recognized by AzaHxP) recognition. To potentially target two consecutive GG bases, new modifications from AzaHx
moiety to 3-Pyr-AzaHx and 2-Pyr-AzaHx moieties were developed. The newly designed
molecules are also small-sized, fluorescent amides with Pyr-AzaHx connected to two conventional
five-membered heterocycles. Complementary biophysical methods were carried out to investigate
DNA binding properties of these molecules. The results showed that neither 3-Pyr-AzaHx nor 2Pyr-AzaHx was able to mimic I-I to specifically target GG dinucleotides. Rather, 3-Pyr-AzaHx
functions like AzaHx or f-I or P-I as a antiparallel stacked dimer. 3-Pyr-AzaHx-PI (2) binds 5’ACGCGT’-3’ with improved binding affinity and high sequence specificity when compared to its
parent molecule AzaHx-PI (1). However, 2-Pyr-AzaHx is detrimental to DNA binding because of
an unfavorable steric clash upon stacking in the minor groove.
3.2

Introduction
Polyamides are a set of well-known DNA-minor groove targeting small molecules that

consist of N-methylpyrrole (P) and/or N-methylimidazole (I) heterocycles (1). Modeled from
naturally occurring DNA binding agents, Netropsin and Distamycin A (2, 3), these molecules can
form 2:1 antiparallel side-by-side stacked dimers upon binding to the DNA minor groove (1, 4).
These molecules interact with DNA by forming specific hydrogen bonds and van der Waals
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contacts with different bases. Such polyamides can be programmed to target any DNA sequence
based on the recognition rules developed by Dervan and coworkers (5, 6). The recent development
of polyamides focuses largely on the synthesis of large hairpin molecules or tandem polyamides
with increased specificity for longer sequences (7, 8) or modified polyamides conjugates that can
serve as DNA probes and enable polyamide with various functions (9, 10). These polyamides
exhibit the ability to manipulate gene expression, thus, advancing the role of polyamides in gene
therapy.
However, challenges still exist for efficient cell uptake. This calls for the development of
small-size, soluble, and stable polyamides that are more easily synthesized. To improve cell
uptake, solubility, stability, and more importantly, the feasibility for nuclear localization testing,
we previously developed a novel class of inherently fluorescent small-size diamino polyamides by
introducing 2-(p-anisyl)-benzimidazole (Hx) moiety to function as two consecutive pyrroles, ‘PP’ or formamido-pyrrole, ‘f-P’ (11, 12). These molecules are hybrids of Hx with two conventional
5-membered heterocycles (P or I). The new Hx-amides can form a 2:1 side-by-side, antiparallel,
stacked homodimer in the DNA minor groove and retain strong DNA binding affinity and
specificity. In addition, the intrinsically fluorescent properties confer these molecules with the ease
of cell study. In a recent study, an extra positive charge was added to Hx-IP at either P or I. These
molecules have demonstrated to not only have higher binding affinity but also improved cell
uptake in NIH3T3 mouse fibroblast cells and A549 cancer cells (13).
To expand the DNA recognition repertoire of Hx-amides and enhance sequence specificity,
we recently reported the design and synthesis of a second generation p-anisyl-AzaHx-amides
(AzaHx-amides) (14). Derived from Hoechst 33258, the AzaHx-amides are structurally similar to
Hx-amides but contain 2-(p-anisyl)-4-azabenzimidazole (AzaHx) moiety at the N-terminus. The
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novel AzaHx moiety mimicked P-I or f-I in DNA recognition and consequently, enabled G/C base
pair recognition of these molecules. Because of the side-by-side, antiparallel stacking manner of
these molecules, introduction of the AzaHx moiety extended DNA site recognition from central
CG (recognized by Hx-I) to central GC (recognized by AzaHx-P, Fig. 5), even CGCG recognition.
Recognized selectively by AzaHx-PI (1), the 5’-ACGCGT-3’ sequence is of great importance,
because it resides in the control region of the human Dbf4 gene promoter: the Mlu1 Cell Cycle
Box (MCB) sequence. Expression of this gene is closely related to the development of several
cancers (15-19).
After successfully establishing that the fluorescent AzaHx moiety functions as f-I or P-I,
we designed new molecules by introducing a pyridyl (Pyr) moiety in place of the p-anisyl moiety
of p-anisyl-AzaHx-amides to further extend the recognition capability of AzaHx polyamides. The
newly introduced pyridyl moiety can potentially function as a H-bond acceptor and target G as
showed by previous literature (20-23). Consequently, we hypothesized that the resulting PyrAzaHx could act as I-I and recognize two consecutive GG base alignments along a DNA sequence.
It was thought that in a 2:1 antiparallel stacked manner, the new molecules would target a GGCC
site.
To test our hypothesis, three different Pyr-AzaHx-amides, namely, 3-Pyr-AzaHx-PI (2), 3Pyr-AzaHx-PP (3), and 2-Pyr-AzaHx-PP (4) (Fig. 3.1) were designed and synthesized. Excitation
of a 1 µM aqueous solution of compound 2 at 310 nm (λmax in uv spectrum) produced a broad
emission from 340 to 440 nm that maximized at about 380 nm. The position of the nitrogen in the
pyridine ring was adjusted to identify the optimal position responsible for stronger binding. Their
predicted cognate sequences are 5‘-ACGCGT-3‘ and/or 5‘-AGGCCT-3‘ for compound 2, 5‘ATGCAT-3‘ and/or 5‘-AGGCCT-3‘ for compound 3, 5‘-AGGCCT-3‘ and/or 5‘-ATGCAT-3‘ for
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compound 4 and the binding schemes are presented in Fig. 3.1. The predicted binding site
maintains central GC base alignment but the immediate flanking bases on both ends are GC rich.
In this study, an extensive series of biophysical methods including DNase I footprinting, thermal
melting (Tm), surface plasmon resonance (SPR), circular dichroism (CD), and Spartan
calculations was employed to investigate the DNA-binding properties of these novel molecules.
The results have provided us with new guidance for development of next stage molecules.
3.3

Materials and Methods
3.3.1

DNA preparation

DNA oligomers were purchased from Eurofins Genomics (for footprinting studies) and
from Integrated DNA Technologies, Inc. (IDT, Coralville, IA, USA) with HPLC purification and
mass spectrometry characterization (for biophysical studies). The oligomers are provided below.
The DNAs used in Tm and CD are short hairpin oligonucleotides, the predicted binding
sites are highlighted in red and the hairpin is written in italic and underlined.
5’-GCAACGCGTACTCTCGTACGCGTTGC-3’ (abbreviated as 5’-ACGCGT-3’)
5’-GCAATGCATACTCCCGTATGCATTGC-3’ (abbreviated as 5’-ATGCAT-3’)
5’-GCAAGGCCTACTTTTGTAGGCCTTGC-3’ (abbreviated as 5’-AGGCCT-3’)
The DNAs used in SPR are hairpin oligonucleotides with biotin attached to the 5’ end, the
predicted binding sites are highlighted in red and the hairpin is written in italic and underlined.
5’-biotin-CCGACGCGTCGGCTCTCCGACGCGTCGG-3’ (abbreviated as 5’-ACGCG
T-3’)
5’-biotin-CGATGCATGCCTCTGCATGCATCG-3’ (abbreviated as 5’-ATGCAT-3’)
5’-biotin-CGAGGCCTGCTCTCAGGCCTCG-3’ (abbreviated as 5’-AGGCCT-3’)
DNA footprinting Each DNA fragment contains 131 base pairs with a [32P]-radiolabeled
5’ end. Highlighted in red are the predicted cognate and non-cognate sites.
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DNA fragment 1 (duplex)
5’-ATGCTCCAGAAAGCCGGCACTCAGTCTACAAACGCGTCATCTTGATCACC
GGTGTTCACAGAAATTTC
3’-TACGAGGTCTTTCGGCCGTGAGTCAGATGTTTGCGCAGTAGAACTAGTGG
CCACAAGTGTCTTTAAAG
TCTAGATCTACACGTAACTCTAGTAGCGCTCTTCAAGCAAGTGGAGCTCTCCT
AACCGACTTT-3’
AGATCTAGATGTGCATTGAGATCATCGCGAGAAGTTCGTTCACCTCGAGAGG
ATTGGCTGAAA-5’*
DNA fragment 2 (duplex)
5’-ATGCTCCAGAAAGCCGGCACTCAGTCTACAAACGCGTCATCTTGATCATG
CATGTTCACAGAAATTTC
3’-TACGAGGTCTTTCGGCCGTGAGTCAGATGTTTGCGCAGTAGAACTAGTAC
GTACAAGTGTCTTTAAAG
TCTAGATCTACTGGTAACTCTAGTATCGATCTTCAAGCAAGTGGAGCTCTCCT
AACCGACTTT-3’
AGATCTAGATGACCATTGAGATCATAGCTAGAAGTTCGTTCACCTCGAGAGG
ATTGGCTGAAA-5’*
DNA fragment 3 (duplex)
5’-ATGCTCCAGAAAGCCGGCACTCAGTCTACAAACGCGTCATCTTGATCAGG
CCTGTTCACAGAAATTTC
3’-TACGAGGTCTTTCGGCCGTGAGTCAGATGTTTGCGCAGTAGAACTAGTCC
GGACAAGTGTCTTTAAAG
TCTAGATCTAGTCCTAACTCTAGTATCGATCTTCAAGCAAGTGGAGCTCTCCT
AACCGACTTT-3’
AGATCTAGATCAGGATTGAGATCATAGCTAGAAGTTCGTTCACCTCGAGAGG
ATTGGCTGAAA-5’*
3.3.2

Compound synthesis and preparation

3-Pyr-AzaHx-PI, (2) 4-Methoxy-3-pyrido-4-aza-benzimidazole-pyrrole-imidazole
Nitro-PI polyamide (24) (60 mg, 0.16 mmol) was hydrogenated over 10% Pd/C in
methanol (20 mL) at room temperature for 16 h. Removal of the catalyst and solvent gave an amine
intermediate as a pale yellow solid that was co-evaporated with dichloromethane twice (5 mL). 3-
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Pyr-Aza-Hx-acid (25) (52 mg, 0.19 mmol) was dissolved in dry DMF (1.5 mL) and the flask was
purged with nitrogen. To the clear solution was added EDCI.HCl (110 mg, 0.6 mmol) followed by
dry triethylamine (0.11 mL, 0.8 mmol) and 1-hydroxybenzotriazole (HOBt) (87 mg, 0.6 mmol)
and stirred for 10 min at room temperature. A solution of the above amine in dry DMF (2.0 mL)
was added to the reaction mixture at room temperature and the flask was again purged with
nitrogen. The reaction mixture was stirred at room temperature for 16 h. The solvent was removed
under pressure (1 mm Hg at 50 °C) and the residue was purified by column chromatography using
silica gel and 7% methanol in chloroform as the eluent system. Concentration of the desired
fractions gave AzaHx-amide 2 as a yellow solid (20 mg, 17%), mp = >230 °C, Rf = 0.50
(1.5:0.2:8.3 methanol: ammonium hydroxide:chloroform); FT-IR (KBr)

3269, 2954, 2825,

1704, 1641, 1530, 1464, 1400, 1363, 1279, 1116, 1099, 1020, 963, 880, 792, 742, 662; 1H-NMR:
(CD3OD)

9.04 (s, 1H), 8.50 (d, J = 8.0 Hz, 1H), 7.94 (s, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.12 (s,

1H), 6.93 (d, J = 8.0 Hz, 1H), 4.02 (s, 3H), 3.99 (s, 3H), 3.97 (s, 3H), 3.49 (t, J = 7.0 Hz, 2H), 2.57
(t, 2H, J = 7.0 Hz), 2.32 (s, 6H); LRMS (ES TOF+) m/z 294 (M+2H2+, 100%), 586 (M+H+, 90%);
HRMS (M+H+) calcd for C28H32N11O4 m/z 586.2638, found 586.2642.
3-Pyr-AzaHx-PP, (3) 4-Methoxy-3-pyrido-4-aza-benzimidazole-pyrrole-pyrrole
The procedure for synthesizing AzaHx-amide 3 was essentially the same as the preparation
of AzaHx-amide 2 except nitro-PP polyamide (24) (60 mg, 0.16 mmol) and 3-Pyr-Aza-Hx-acid
(25) (52 mg, 0.19 mmol) were used. Purification of the crude product by column chromatography
using silica gel and 6% methanol in chloroform as the eluent system gave the desired product 3 as
a pale yellow solid (26 mg, 26%), mp = 240-244 °C, Rf = 0.49 (1.5:0.2:8.3 methanol: ammonium
hydroxide:chloroform); FT-IR (KBr)
1021, 812, 763, 660; 1H-NMR: (CD3OD)

3160, 3045, 2927, 2887, 1620, 1586, 1460, 1397, 1278,
8.98 (d, J = 4.0 Hz, 1H), 8.43 (dd, J = 4.0 Hz, 8.0 Hz,
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1H), 8.02 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.39 (d, J = 2.0 Hz, 1H), 7.20 (d, J = 2.0
Hz, 1H), 7.03 (d, J = 2.0 Hz, 1H), 6.96 ( , J = 8.0 Hz, 1H), 6.81 (d, J = 2.0 Hz, 1H), 4.00 (s, 3H),
3.94 (s, 3H), 3.88 (s, 3H), 3.34 (t, J = 7.0 Hz, 2H), 2.43 (t, J = 7.0 Hz, 2H), 2.29 (s, 6H), 1.79
(quint, J = 7.0 Hz, 2H); LRMS (EI) m/z 300 (M+2H2+, 100%), 599 (M+H+, 100%); HRMS (M+H+)
calcd for C30H35N10O4 m/z 599.2842, found 599.2851.
2-Pyr-AzaHx-PP, (4) 3-Methoxy-2-pyrido-4-aza-benzimidazole-pyrrole-pyrrole
Synthesis of AzaHx-amide 4 followed the same procedure as the preparation of AzaHxamide 2 except nitro-PP polyamide (24) (60 mg, 0.16 mmol), 2-Pyr-Aza-Hx-acid (25) (48 mg,
0.18 mmol), and a 6% methanol in chloroform solvent system was used to purify product 4, That
was isolated as a pale yellow solid (32 mg, 35%), mp: 170-174 °C (decomposition), Rf = 0.22
[MeOH: CHCl3 (80:20)]; FT-IR (KBr)

3305, 2920, 1738, 1717, 1680, 1655, 1635, 1576,

1538, 1463, 1436, 1373, 1318, 1258, 1193, 1130, 1096, 1010, 888, 768; 1H-NMR: (DMSO-D6 +
3 drops of D2O)

9.92 (s, 1H), 8.08 (s, 1H), 7.99 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H),

7.40 (s, 1H), 7.21 (s, 2H), 6.84 (s, 1H), 4.00 (s, 3H), 3.88 (s, 3H), 3.81 (s, 3H), 3.16 (t, J = 8.0 Hz,
2H), 2.24 (t, J = 8.0 Hz, 2H), 2.14 (s, 6H), 1.61 (quint, J = 6.5 Hz, 2H); LRMS (TOF ES+) m/z 300
(M+2H2+, 20%); 599 (M+H+, 22%); HRMS (M+H+) calcd for C30H35N10O4 m/z 599.2842, found
599.2849.
Preparation of the compounds For the biophysical studies, each compound was initially
dissolved in methanol, then three equivalent amount of HCl was added to the solution and the
mixture was stirred for 10 min. The mixture was evaporated to dryness using argon gas before the
residue was dissolved in double deionized water.
The extinction coefficient of AzaHx-amides 3-Pyr-AzaHx-PI (2), 3-Pyr-AzaHx-PP (3) and
2-Pyr-AzaHx-PP (4) were determined by UV-vis spectrometer at wavelengths 310 nm, 310 nm
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and 316 nm, respectively. The determined extinction coefficient values are 22990 L/mole-1·cm-1,
19853 L/mole-1·cm-1 and 10117 L/mole-1·cm-1, respectively. The buffer used for the determination
contains 10 mM sodium phosphate, 1 mM EDTA, pH 6.2.
For DNase I footprinting studies, each AzaHx-amide was dissolved in DMSO to give a 10
mM stock concentration and stored at -20°C, and diluted to appropriate concentrations just before
use.
3.3.3

Biophysical experimental procedures

Thermal melting (Tm) Thermal melting was carried out on a Cary 300 Bio UV/visible
spectrophotometer (Varian) at a concentration of 6 µM ligand and 3 µM DNA. The samples were
warmed up from 25 °C to 95 °C. All experiments were performed in 10-mm path length quartz
cells. Tm values were determined at the reflection points of the melting curves. The ΔTm values
are the difference between melting temperature of DNA-ligand complex and free DNA. The buffer
used for Tm contained 10 mM sodium phosphate, 1 mM EDTA, at pH 6.2.
Surface Plasmon Resonance (SPR) The binding study was conducted on a four-channel
Biacore T200 surface plasmon resonance instrument. Three biotinylated DNAs (5’-biotinCCGACGCGTCGGCTCTCCGACGCGTCGG-3’, 5’-biotin-CGATGCATGCCTCTGCATGCA
TCG-3’, 5’-biotin-CGAGGCCTGCTCTCAGGCCTCG-3’) are immobilized on a streptavidin
functionalized sensorchip through the last three channels, respectively. The first channel has no
DNA immobilized for baseline correction. The DNA immobilization procedure is the same as
previously described. (26) The first 5 cycles are pure buffer injection serving as double baseline
correction to remove any instrumental errors. Molecules are injected over the chip surface at an
increasing gradient of concentration for 180 s each cycle, followed by a pure running buffer
injection to dissociate the complex. The running buffer consists of 10 mM cacodylic acid, 100 mM
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NaCl, 1mM ethylenediaminetetraacetic acid (EDTA) and 0.05% v/v surfactant Polysorbate 20
(P20), pH 6.2. 1 M NaCl was used as regeneration buffer at the end of each cycle to fully dissociate
the molecule and prepare the surface for the next cycle. The binding kinetics were determined by
1:1 global kinetic fitting with mass transfer correction incorporated. In some cases, the kinetics
were so fast that they went beyond the limit of detection. Affinities were then obtained through
steady state fitting for those that had reached equilibrium during molecule injection.
Circular Dichroism (CD) Circular Dichroism was performed on a Jasco J-810 spectrometer
(Jasco Inc., Easton, MD) at ambient temperature with a scan range of 400-220 nm. A DNA
concentration of 5 µM was firstly scanned followed by a titration of AzaHx-amides 2 and 3 in
increments of 0.5 equivalents. The spectra were averaged over four scans with a scan speed of 50
nm·min-1 and a buffer blank correction. All experiments were conducted in phosphate A PO40
buffer (10 mM sodium phosphate, 1 mM EDTA, pH 6.2)
Molecule Visualization Spartan´16 software was used to calculate the compounds. Energy
profile method at ground state with density functional B3LYP/6-31G* in vacuum was applied for
calculation. The molecules were then manually aligned for observation.
DNase I footprinting The DNase I footprinting reactions were conducted in a total volume
of 8 μL; the labelled DNA substrate (2 μL, 200 counts s-1 ) was incubated for 1 h at room
temperature in 4 μL TN buffer (10 mM Tris-HCl, 10 mM NaCl, pH 7.0) containing the required
polyamide concentration. Controlled digestion with RQ1 RNase-Free DNase I (Promega) was then
initiated by the addition of 2 μL of DNase I solution (20 mM NaCl, 2 mM MgCl2 , 2 mM MnCl2
, DNase I 0.02U, pH 8.0), mixed gently and allowed to proceed for 3 min at room temperature and
terminated by snap freezing the samples on dry ice. The nuclease-digested samples were
subsequently lyophilized to dryness and resuspended in 10 μL of formamide loading dye (95%
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formamide, 20 mM EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol). A purine specific
DNA marker was prepared to allow identification of the guanine and adenine residues in the
sequence. 3 μL of radiolabelled DNA substrate was heated at 90°C for 20 min in the presence of
20 μL TN buffer and 5 μL of formamide loading dye. Alternatively, 10 μL of radiolabelled DNA
substrate was incubated at room temperature for 5 min with 50 μL formic acid (Sigma-Aldrich),
and then frozen on dry ice and lyophilized to dryness. 65 μL of piperidine (1 M; Sigma-Aldrich)
was then added and the sample was heated at 90°C for 30 min before the reaction was terminated
by snap freezing on dry ice and lyophilised to dryness. The DNA marker was then washed with
distilled water, lyophilised and resuspended in 10 μL of formamide loading dye.
The samples were denatured by heating at 90°C for 4 min, and then transferred on to ice
before loading on a 10% denaturing polyacrylamide gel containing urea (UreaGel, National
Diagnostics, UK). Electrophoresis was carried out for 2-4 h at 1650 V (~70W, 55°C) in 1x
Trisborate EDTA buffer (TBE; Severn Biotech). The gel was then transferred onto Whatman 3MM
paper and dried under vacuum at 80°C for 2 h using a GD 2000 gel dryer (Hoefer). The gel was
exposed overnight to Fuji medical X-Ray film and developed using a Konica Medical Film
Processor SRX-101A to visualise the radioactive signal.
3.4

Results
3.4.1

Determination of relative DNA binding strength of Pyr-AzaHx polyamides

using thermal melting (Tm)
To test the binding of these newly designed molecules to their predicted DNA sites, thermal
melting experiments were carried out. ΔTm, the difference of melting temperature of the bound
DNA complexes and melting temperature of DNA alone, reflects the extent to which DNA is
stabilized by the molecules, and thus the relative binding strength. The ΔTm results of three
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molecules and their predicted cognate DNAs are listed in Table 3.1. It is clear that 3-Pyr-AzaHxPI (2) binds to both 5’-ACGCGT-3’ and 5’-ATGCAT-3’ sequences quite strongly (15.9 °C and
15.5 °C, respectively), but does not have high affinity for 5’-AGGCCT-3’ (8.8 °C). With 3-PyrAzaHx-PP (3), strong binding to 5’-ATGCAT-3’ (14.5 °C) and weak binding to 5’-AGGCCT-3’
(7.8 °C) and 5’-ACGCGT-3’ (7.4 °C) were observed. These results suggest that the 3-Pyr-AzaHx
moiety functions similarly to p-anisyl-AzaHx or f-I or PI and that the pyridine group does not
make specific H-bond contacts with G. Thus, the observed target sequences of 3-Pyr-AzaHx-PI
(2) and 3-Pyr-AzaHx-PP (3) are ACGCGT and ATGCAT, respectively.
We then modified the 3-Pyr-AzaHx by relocating the nitrogen to meta-position (Fig. 3.1).
The resulting 2-Pyr-AzaHx-PP (4) was tested against the three DNAs for its role in stabilization.
Surprisingly, 2-Pyr-AzaHx-PP (4) showed hardly any affinity for all three DNAs.
3.4.2

Determination of DNA selectivity of Pyr-AzaHx polyamides by DNase I

footprinting
DNase I footprinting was conducted to further investigate and compare the behavior of
these molecules on a larger DNA scale. The binding affinity and selectivity of 3-Pyr-AzaHx-PI
(2) was investigated using an engineered DNA fragment 1 that consists of the cognate sequence
(based on Tm results): 5’-ACGCGT-3’, as well as four mutant/non-cognate sites: 5’-ACCGGT3’, 5’-AAATTT-3’, 5’-ACACGT-3’, and 5’-AGCGCT-3’ (Fig. 3.3A). The footprinting gel of 3Pyr-AzaHx-PI (2) showed a clear footprint beginning at 0.5 µM for the cognate sequence (Fig.
3.3A), exhibiting a similar binding pattern to AzaHx-PI (1) (Fig. 3.5A) (14). Only a very weak and
incomplete single mismatch protection site is shown at the sequence, 5’-ACACGT-3’, indicating
a weak tolerance of 3-Pyr-azaHx as well as azaHx (Fig. 3.5A) for a “A” over its preferred “G”.
No other significant protection sites were evident at concentrations of up to 20 µM with this DNA
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sequence. The Tm and footprinting data together indicate that the 3-Pyr-AzaHx-PI (2) is very
selective for the central GC dinucleotides recognition, with a selection factor of more than 40 fold
according to the footprinting studies.
The DNA binding property of 3-Pyr-AzaHx-PP (3) was evaluated using engineered DNA
fragment 2 (Fig. 3.3B). The molecule is predicted to target 5’-WWGCWW-3’ (W = A or T). Two
cognate sequences: 5’-ATGCAT-3’ and 5’-AAGCAA-3’, along with four non-cognate sites: 5’ACGCGT-3’, 5’-AAATTT-3’, 5’-ACTGGT-3’, and 5’-ATCGAT-3’ were present in DNA
fragment 2. A clear footprint was visible at both consensus sequences starting at 3 µM. However,
evident footprint was also detected at the non-cognate site containing flipped central GC pair: 5’ATCGAT-3’ at 3 µM. The equally strong protection of this non-cognate site and the featured
central base pair indicates that the molecule might bind to the sequence in the reversed orientation,
that is, N-terminus of the molecule is aligned with 3’ end of DNA. What also appeared on the gel
was another footprint at 5’-ACTGGT-3’ at 10 µM (Fig. 3.3B). The footprinting result suggests
that 3-Pyr-AzaHx-PP (3) not only binds weakly to its cognate 5’-ATGCAT-3’ sequence compared
to 3-Pyr-AzaHx-PI (2), but also has poor sequence selectivity, as evidenced by the off-target
binding sites.
With the lack of binding according to the results from Tm studies, further investigation on
2-Pyr-AzaHx-PP (4) was conducted using a broad spectrum of DNA sequences to determine
whether it resembles AzaHx-PP, recognizing 5’-WWGCWW-3’, or IIPP, recognizing 5’WGGCCW-3’. DNase I footprinting of 2-Pyr-AzaHx-PP (4) binding to DNA fragment 2 that
contains two 5’-WWGCWW-3’ sites (5’-ATGCAT-3’ and 5’-AAGCAA-3’) was carried out. No
footprint was detected up to 25 µM (Fig. 3.4A). On another trial using the engineered fragment 3
containing 5’-WGGCCW-3’ (5’-AGGCCT-3’), the results showed no binding up to 50 µM (Fig.
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3.4B). These results agree with those collected from Tm studies, indicating that a change in the
nitrogen position along with the attached methoxy unit at the 3-position of the pyridyl group at the
N-terminus abrogated the binding of Pyr-AzaHx moiety, thus, making it incompetent structural
element of design to target any DNA site.
3.4.3

Determination of binding kinetics and affinity of Pyr-AzaHx polyamides by SPR

SPR provides us with real-time information to quantitatively determine the interaction
between molecules and DNAs. After confirming the corrected cognate DNA for each molecule
and to assist evaluation of binding affinity and kinetics compared to previous work, SPR
experiments were carried out with three predicted cognate DNA sequences that are immobilized
on a sensorchip. The resulting SPR sensorgrams are shown in Fig. 3.6 and the kinetic and
equilibrium binding constants are listed in Table 3.2. The strongest binding was observed between
3-Pyr-AzaHx-PI (2) and its cognate DNA, 5’-ACGCGT-3’ (KD = 0.75 ± 0.01 nM), followed by
its interaction with 5’-ATGCAT-3’ (KD = 3.2 nM). The result shows that 3-Pyr-AzaHx-PI (2) is
very specific to the central GC base alignment, but not very selective for the immediate flanking
bases, especially among C, A or T. Strong interactions between 3-Pyr-AzaHx-PP (3) and its
cognate DNA, 5’-ATGCAT-3’ were also confirmed by SPR with KD equals 1.1 nM. These results
are in good agreement with both Tm and footprinting data within error range, indicating that the
molecules are well stacked and form strong hydrogen bonding with DNA base pairs. The strong
interactions are also featured by very slow dissociation rate (~10-4·s-1, Table 3.2, Fig. 3.6). On the
other hand, 3-Pyr-AzaHx-PP (3) was found to bind very weakly to 5’-ACGCGT-3’ (KD = 1035 ±
22nM), suggesting that a switch of the molecule structure from I to P is incompatible with G. Also
consistent with the Tm result is the fact that 3-Pyr-AzaHx-PI (2) binds to the mismatched sequence
5’-AGGCCT-3’, albeit with significantly reduced affinity compared to its cognate DNA. If 3-Pyr-
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AzaHx interacts with GG to some extent, then 3-Pyr-AzaHx-PP (3) should target 5’-AGGCCT-3’
according to the binding scheme depicted in Fig. 3.1. To our surprise, 3-Pyr-AzaHx-PP (3)
exhibited around 10 times weaker affinity to 5’-AGGCCT-3’, indicating that the 3-Pyr-AzaHx
moiety is not the determinant factor in this binding event. In an attempt to specifically recognize
two consecutive GG base pairs, 3-Pyr-AzaHx was modified to 2-Pyr-AzaHx moiety and the
binding of 2-Pyr-AzaHx-PP (4) was tested on SPR against the three DNA sequences. In agreement
with the Tm data, 2-Pyr-AzaHx-PP (4) binds very weakly to 5’-ACGCGT-3’ and 5’-ATGCAT-3’
and showed no binding at all to 5’-AGGCCT-3’. Clearly, the relative position of the pyridine
nitrogen along with the methoxy group is pivotal for binding. A close observation of the
sensorgram shows that some fitting curves are diverged from experimental data. Especially, the
experimental deviations are above the global fit. This indicates that non-specific binding begins to
occur at higher concentrations.
3.4.4

Confirmation of binding of Pyr-AzaHx polyamides in DNA minor groove by CD

The binding mode of Pyr-AzaHx polyamides to their cognate DNA was evaluated by CD.
Molecules that bind in the minor groove typically have positively induced band (25, 27-29). The
Pyr-AzaHx molecules alone do not generate any peak. Upon titration of 3-Pyr-AzaHx-PI (2) and
3-Pyr-AzaHx-PP (3) to their cognate DNA, strong positive signals are induced at 350 nm for both
molecules (Fig. 3.7).This is typical for polyamides and Hx-amides and is indicative of DNA minor
groove binding.
3.5

Discussion
Previous development of hairpin polyamides involved incorporation of benzimidazole (Bi)

or imidazolepyridine (Ip) into the polyamide core structure and showed that the resulting
molecules displayed strong binding affinity and sequence specificity (30-34). The need for more
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soluble, smaller polyamides to improve cell uptake and biological functions requires new strategies
to design the molecules. Our previously designed small-size p-anisyl-Hx-amides mimic f-P or PP, form antiparallel stacked dimer, and follow pyrrole-imidazole DNA recognition principles (1,
4). Biological studies of Hx-amides, specifically, Hx-IP targeting the inverted repeat of CCAAT
Box 2 on the topoisomerase IIα promoter to inhibit NF-Y binding, have shown increased cell
uptake and enhanced subsequent biological activities in NIH3T3 and A549 cells compared to high
molar mass polyamides, such as hairpins and H-pins (35-38). The improved cell permeability and
DNA binding affinity from incorporating N-terminal p-anisyl-Hx moiety in small Hx-amides
offers a promising way for designing small-size, soluble polyamides. However, the P-P like DNA
binding property of p-anisyl-Hx is limited to A or T recognition. Especially, according to the
central and terminal pairing rules (Fig. 3.8), the central two heterocycle pairs of a tri-amide or
tetra-amide homodimer recognize the two central base pairs while the terminal formamido and
imidazole/pyrrole (tri-amides) or the two “outer” heterocycles pairs (tetra-amides) specifically
target the immediate flanking base pairs on either side of the central base pairs (39, 40). Therefore,
by this recognition pattern, Hx-amides are restricted to central CG dinucleotide recognition and
the subsequent target of biologically relevant sequences is constrained (Fig. 3.8).
The novel development of AzaHx-amides showed strong binding affinity and additional
GC selectivity. The AzaHx moiety functions as an alternative to f-I or P-I capable of forming an
antiparallel dimer. According to the central and terminal pairing rule, AzaHx-amides are able to
confer central and outer GC dinucleotide recognition (Fig. 3.8), thus greatly extending the
sequence it can target.
To further expand the recognition repertoire to GGCC, our new modification strategy is to
replace the p-anisyl group in AzaHx-amdies with pyridyl groups to generate Pyr-AzaHx-amides.
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The central GC dinucleotide is unchanged, as is the AzaHx moiety. The extra nitrogen of Nterminal pyridyl moiety could provide an additional hydrogen bond acceptor for G recognition. To
test this hypothesis, the DNA binding properties of the modified Pyr-AzaHx-amides are
investigated by a complementary set of biophysical and biochemical methods.
3.5.1

Tm results show that 3-Pyr-AzaHx functions similarly to AzaHx or P-I or f-I

Tm studies were performed to initially screen the Pyr-azaHx complexes for binding DNA.
The prediction was that Pyr-AzaHx would act similarly to two consecutive imidazole units, or I-I,
to selectively recognize GG dinucleotides. But the low ΔTm value of 3-Pyr-AzaHx-PP (3) with
5’-AGGCCT-3’ and high value with 5’-ATGCAT-3’ (Table. 3.1) suggested that 3-Pyr-AzaHx
could not form extra hydrogen bonds with two consecutive GG dinucleotides to stabilize the
molecule-DNA complex. Rather, the 3-Pyr-azaHx moiety behaved more akin to AzaHx or P-I or
f-I, and it anchored itself in the minor groove of TG dinucleotides with strong hydrophobic
contacts. Evidence of the high ΔTm value of 3-Pyr-AzaHx-PI (2) with 5’-ACGCGT-3’ and low
value with 5’-AGGCCT-3’ further confirmed the similar functionality of 3-Pyr-AzaHx to AzaHx.
It is highly possible that the more polar nitrogen atom of the pyridyl moiety, compared to the
opposite methinyl group, is rotated away from the floor of minor groove or is not positioned
properly for hydrogen bonding. Instead, similar to pyrrole binding units, the hydrophobic C-H
units in the pyridyl group were directed more favorably toward the hydrophobic floor in the minor
groove. Thus, the preferred cognate binding sites for 3-Pyr-AzaHx-PI (2) and 3-Pyr-AzaHx-PP (3)
were 5’-ACGCGT-3’ and 5’-ATGCAT-3’, respectively. It was also noticeable that 3-Pyr-AzaHxPI (2) bound with high affinity to the mismatch site 5’-ATGCAT-3’, indicating that when G was
not available, imidazole could tolerate an A/T base pair quite well, thus compromising its
selectivity. This result agreed with our previous work that showed imidazole on imidazole stacking
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in polyamides bound preferentially to T/G or G/T but it tolerated C/G and G/C base pairs (29, 4143).
The extremely low ΔTm values of the modified 2-Pyr-AzaHx-PP (4) to any of the three
sequences indicate that the position of the pyridine nitrogen along with the methoxy group can be
quite important to DNA binding. In fact, to structurally visualize the relative position of the
antiparallel stacked homodimer, Spartan´16 software was used for Molecular Mechanics
calculation. Our models show that when two 2-Pyr-AzaHx-PP (4) molecules are anti-parallely
stacked, the bulky 3-methoxy group attached to pyridine is sterically encumbered with the Nmethyl group of the C-terminal pyrrole (Fig. 3.9). On the other hand, if the nitrogen of pyridine is
attracted toward the minor groove floor, the 3-methoxy group appears to be too big and it also
affects the stacking of two molecules. It is difficult for the minor groove to accommodate
favorably. Therefore, either way the nitrogen is pointing, the 3-methoxy-2-pyridyl moiety would
encounter steric clash upon binding to DNA as stacked dimer, resulting in thermodynamically
unstable molecule-DNA complex.
3.5.2

Binding affinity and selectivity of 3-Pyr-AzaHx-amides

The sequence specificity of the new AzaHx-amides was investigated by DNase I
footprinting. 3-Pyr-AzaHx-PI (2) showed a clear footprint toward 5’-ACGCGT-3’ at 0.5 µM and
more than 40-fold selectivity against the tested DNA fragment. This is very similar in terms of
both affinity and selectivity, to its parent structure, AzaHx-PI (1), in which the AzaHx moiety
contains p-anisyl instead of a pyridyl group. AzaHx-PI was previously reported to footprint at 5’ACGCGT-3’ using the same DNA fragment starting at 0.5 µM with at least 40-fold selectivity
(Fig. 3.5A) (14). Since 3-Pyr-AzaHx is experimentally shown to function as AzaHx or P-I or f-I,
two other AzaHx-amide analogs recognizing the same cognate DNA were also included into the
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comparison (40, 44-46). On the same DNA fragment, f-IPI (44, 45), a N-formamido
pyrrole/imidazole polyamide, generated a footprint at the cognate site, beginning at 0.05 µM.
However, another clear footprint at 5’-AGCGCT-3’ is produced at 1 µM, suggesting that the
sequence selectivity of f-IPI is reduced even though it has relatively high binding affinity. On the
other hand, PIPI (44), a non-formamido pyrrole/imidazole polyamide, footprinted starting at 1 µM
but showed comparable sequence selectivity to 3-Pyr-AzaHx-PI (2).
With a slightly lower binding affinity than 3-Pyr-AzaHx-PI (2), 3-Pyr-AzaHx-PP (3)
footprinted at 3 µM at its cognate site 5’-ATGCAT-3’. At the same concentration, another
footprint appeared at 5’-ATCGAT-3’. Given the inverted central bases and the degenerate P/P
recognition of A/T or T/A, it is likely that the molecule can bind in a reversed manner. Another
footprint for 5’-ACTGGT-3’ at 10 µM indicates that 3-Pyr-AzaHx-PP (3) is not very selective.
When compared to its analogs that target the same cognate DNA, AzaHx-amide 3 showed higher
binding affinity. AzaHx-PP, which also contains p-anisyl instead of a pyridyl group, generated a
footprint at 10 µM at the cognate site, but one other footprint at 5’-ATCGAT-3’ at 15 µM,
indicating that AzaHx-PP could not differentiate the two sequences very well, either (Fig. 3.5B).
For f-IPP, even though a clear footprint at the cognate sequence was evident at 3 µM, equally
strong footprint also appeared at three non-cognate sequences (Fig. 3.5C). These results suggest fIPP has low selectivity. Taken together, 3-Pyr-AzaHx-PP (3) exhibited stronger binding affinity
with slightly compromised selectivity compared to other structurally similar compounds.
To more accurately compare the binding affinities, SPR was performed to obtain the
binding kinetics and equilibrium binding affinities of the new molecules and three DNA
sequences. The SPR results are in good agreement with Tm and footprinting data. Interestingly,
the binding affinity of 3-Pyr-AzaHx-PI (2) (KD = 0.75 nM) is much higher than its analogs: AzaHx-
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PI (1) (KD = 400 nM) (14), f-IPI (KD = 19 nM) (39, 44), and PIPI (KD = 7100 nM) (44) on binding
to the cognate sequence, 5’-ACGCGT-3’. These results reveal that 3-Pyr-AzaHx-PI (2) has
drastically improved affinity, at least 20 times over its previously reported analogs. In particular,
3-Pyr-AzaHx-PI (2) has much higher binding affinity than its closest analog and parent structure
AzaHx-PI (1). When comparing 3-Pyr-AzaHx-PP (3) (KD = 1.1 nM) to its analogs AzaHx-PP (KD
= 110 nM, data not published) and f-IPP (KD = 120 nM) (39), 3-Pyr-AzaHx-PP (3) showed around
100 times higher binding affinity. These results together with the footprinting data suggest that the
3-Pyr-AzaHx moiety helps to improve binding affinity while maintains a reasonable level of
selectivity.
Interestingly, in a separate study reported recently by us, adding an extra positive charge
to Hx-amides showed that the resulting dicationic HxIP* and HxI*P have higher binding affinity
but reduced selectivity toward their consensus site 5’-ATCGAT-3’ (ΔTm = 32 °C and 30 °C,
respectively) than their mono-charged analog, HxIP (ΔTm = 15 °C) (13). Therefore, we suspect
that the high affinity of 3-Pyr-AzaHx-amides is due to protonation of the nitrogen on the pyridyl
moiety, thus contributing to an extra positive charge for stronger attraction to the negatively
charged DNA. In fact, previous literatures have also shown that increasing positive charges can
facilitate DNA binding (47-49). To test this idea, the binding of 3-Pyr-AzaHx-PI (2) to 5’ACGCGT-3’ was performed by SPR at pH 9.0. The resulting affinity was lowered by about 16
times than that at pH 6.2 (Fig. 3.10), thus indicating that the increased binding affinity of 3-PyrAzaHx-PI (2) could be attributed to the protonation of the pyridine nitrogen. Altogether, these
results suggest that modification of the N-terminal p-anisyl to N-terminal pyridiyl, or converting
AzaHx to 3-Pyr-AzaHx not only retained comparable selectivity but also significantly improved
binding affinity under biological conditions.
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3.6

Conclusion
In this study, we have designed and synthesized a novel class of small-sized polyamides,

aiming to expand the DNA recognition repertoire to GGCC sequence. Our complementary
biochemical and biophysical studies have shown that although the newly designed Pyr-AzaHx
amides do not specifically recognize GG dinucleotides, the 3-Pyr-AzaHx amides do possess
improved functionality compared to previous analogs. Especially, the increased binding affinity
under biological conditions could be due to protonation of the pyridine nitrogen. The results have
greatly extended our knowledge on molecular interactions and thus compound modification and
optimization. Meanwhile, challenges on designing GG dinucleotides targeting, fluorescent
compounds with good cell uptake are still needed.
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3.9

Tables and Figures

Figure 3.1 Structures and schematic presentation of predicted binding to DNA sites of
three Pyr-AzaHx polyamides.
Blue rectangles represent 3-Pyr-AzaHx moiety, empty squares represent pyrrole, filled
squares represent imidazole, and orange rectangles represent 2-Pyr-AzaHx group. 2Pyr-AzaHx-PP has two predicted recognition sites.
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Figure 3.2 Synthetic schemes of compound 2-4.

Table 3.1 Thermal melting profile of three Pyr-AzaHx polyamides binding to their predicted
cognate sequences and mutant sequences

Tm of DNAs ( °C)

CGCG

TGCA

GGCC

68.8

61

67.2

ΔTm (°C)

Polyamides
3-Pyr-AzaHx-PI (2)

15.9

15.5

8.8

3-Pyr-AzaHx-PP (3)

7.4

14.5

7.8

2-Pyr-AzaHx-PP (4)

1.2

0.8

0
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3-Pyr-AzaHx-PI (2)

3-Pyr-AzaHx-PP (3)

Figure 3.3 Autoradiograms of DNase I footprinting gels corresponding to 3-Pyr-AzaHxPI, 2 (A) and 3-Pyr-AzaHx-PP, 3 (B).
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The DNA binding properties of 2 and 3 were assessed using DNA fragment 1 and 2,
respectively. The appropriated 32P-radiolabelled DNA fragment was incubated for 1 h
at room temperature in TN buffer (10 mM Tris-HCl, 10 mM NaCl, pH 7.0) containing
the required polyamide concentration. DNase I digestion was initiated by the addition
of DNase I solution (20mM NaCl, 2mM MgCl2, 2mM MnCl2, DNase I 0.02U, pH 8.0)
and was terminated after 3 min by snap freezing the samples on dry ice. Following
lyophilization and resuspension in formamide loading dye (95% formamide, 20 mM
EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol), the cleavage products of
the DNase I digestion reactions were resolved on 10% polyacrylamide gels. The
concentrations (μM) used are shown at the top of each gel. 0; controlled cleavage
reaction, containing no drug. The cognate sequences are labelled red and the noncognate sites are also indicated. Asterisk marks the concentration (µM) at which
footprints become evident. G+A represents a formic acid-piperidine marker specific
for purines.
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DNA fragment 2

DNA fragment 3

Figure 3.4 Autoradiogram of the DNase I footprinting gel of 2-Pyr-AzaHx-PP on A)
DNA fragment 2 and B) DNA fragment 3.
The cognate sequences are labelled red and the non-cognate sites are also indicated.
Asterisk marks the concentration (µM) at which footprints become evident. G+A
represents a formic acid-piperidine marker specific for purines.
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A

B

C

Figure 3.5 Autoradiogram of the DNase I footprinting gel of A) AzaHx-PI on DNA fragment
1 and B) AzaHx-PP and C) f-IPP on DNA fragment 2.
The cognate sequences are labelled red and the non-cognate sites are also indicated.
Asterisk marks the concentration (µM) at which footprints become evident. G+A represents
a formic acid-piperidine marker specific for purines.

89

C
5’-Biotin-CCGACGCGTCGG T
GGCTGCGCAGCC C
T

C
5’-Biotin-CGATGCATGC T
GCTACGTACG C
T

C
5’-Biotin-CGAGGCCTG T
GCTCCGGAC C
T

Figure 3.6 SPR sensorgrams of Pyr-AzaHx polyamides binding to different DNAs.
The DNA sequences are listed at the top of the column and the compounds are specified on
each sensorgram. The whole sequences of the DNAs are listed in the Supporting Information.
The colored lines are experimental data and the black overlays are kinetic fitting. The
sensorgram at the bottom left corner was fitted with steady state fitting and bottom right corner
sensorgram shows no binding. The buffer used for SPR is 10 mM cacodylic acid, 100 mM
NaCl, 1mM EDTA and 0.05% v/v surfactant Polysorbate 20 (P20), pH 6.2, 25°C.
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Table 3.2 Kinetic rate constants and equilibrium constants derived from SPR
Compound
3-PyrAzaHx-PI

3-PyrAzaHx-PP

2-PyrAzaHx-PP

DNA

ka (x104 M-1s-1)

kd(x10-3s-1)

KD (nM)

ACGCGT

16 ± 0.3

0.12 ± 0.001

0.75 ± 0.01

ATGCAT

40 ± 0.7

1.30 ± 0.01

3.20 ± 0.2

AGGCCT

1.70 ± 0.5

6.60 ± 0.03

397 ± 17

ACGCGT

3.30 ± 0.03

34 ± 0.04

1035 ± 22

ATGCAT

35 ± 0.2

0.40 ± 0.001

1.10 ± 0.03

AGGCCT

1.00 ± 0.01

40 ± 0.4

3996 ± 472

ACGCGT

ND[a]

ND[a]

1420 ± 700

ATGCAT

2.30 ± 0.02

16 ± 0.06

698 ± 237

AGGCCT

NB

[b]

NB

[b]

NB [b]

[a] The values are too fast to be determined. [b] No binding is detected.

Figure 3.7 CD spectra depicting 3-Pyr-AzaHx molecules (2) and (3) binding to their
cognate DNAs, respectively.
The DNA sequences are listed in Supporting Information. The buffer consists of 10 mM
sodium phosphate, 1 mM EDTA, pH 6.2.
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Hx-IP

AzaHx-PP
Central

Central

5’- A T C

G A T -3’

5’- A T G

C A T -3’

+
+

+
+

3’- T A G

C T A -5’

3’- T A C

Terminal

G T A -5’

Terminal

Figure 3.8 Central and terminal pairing rules illustrated by different binding of Hx-IP
and AzaHx-PP.
The central and terminal base pairs are indicated in pink and green boxes, respectively.

2-Pyr-AzaHx-PP
(4)

3-Pyr-AzaHx-PP
(3)

3-Pyr-AzaHx-PI (2)

Figure 3.9 Stacked models of all three molecules from Spartan calculations.
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Figure 3.10 SPR sensorgrams and equilibrium binding constants of 3-Pyr-AzaHx-PI
under different pH.
The buffer used at pH 6.2 is consisted of 10 mM cacodylic acid, 100 mM NaCl, 1mM
EDTA and 0.05% v/v surfactant Polysorbate 20 (P20), 25°C. The buffer at pH 9.0
contains 50 mM Tris-HCl, 100 mM NaCl, 1mM EDTA and 0.05% v/v P20, 25°C. The
whole sequence of 5‘-ACGCG-3‘ is listed in the Supporting Information.
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4.1

Abstract
Hairpin polyamides are synthetic small molecules that bind DNA minor groove sequence-

selectively and, in many sequences, induce widening of the minor groove and compression of the
major groove. The structural distortion of DNA caused by polyamides has enhanced our
understanding of the regulation of DNA-binding proteins via polyamides. Polyamides have DNA
binding affinities that are comparable to those proteins, therefore, can potentially be used as
therapeutic agents to treat diseases caused by aberrant gene expression. In fact, many diseases are
characterized by over- or under-expressed genes. PU.1 is a transcription factor that regulates many
immune system genes. Aberrant expression of PU.1 was associated with the development of acute
myeloid leukemia (AML). We have, therefore, designed and synthesized ten hairpin polyamides
to investigate their capacity in controlling the PU.1-DNA interaction. Our results showed that nine
of the polyamides disrupt PU.1-DNA binding and the inhibition capacity strongly correlates with
binding affinity. One molecule, FH1024, was observed forming a FH1024-PU.1-DNA trimer
instead of inhibiting PU.1-DNA binding. This is the first report of a small molecule that is
potentially a weak agonist that recruits PU.1 to DNA. The finding sheds light on the design of
polyamides that exhibit novel regulatory mechanisms on protein-DNA binding.
4.2

Introduction
Polyamides (PAs) are sequence-selective DNA minor groove binders that are composed of

N-methylpyrrole (Py) and N-methylimidazole (Im) heterocycles (1, 2). Hairpin PAs are formed by
covalently linking two PA strands side-by-side, typically by using γ-aminobutyric acid (a γ-turn)
to enhance DNA binding affinity and specificity (3, 4). Upon binding to DNA, Py/Py recognizes
both T/A and A/T base pairs, while the Im/Py pair distinguishes G/C from C/G (5-8). PAs can be
programmed to target selectively many predetermined DNA sequences according to the reported
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binding rules, enabling very potent interactions with DNA that are comparable with or stronger
than interactions of DNA-binding proteins (2, 5, 6, 8-11). In addition, hairpin PAs have also been
shown to be cell permeable (12-15). Therefore, PAs are promising agents that can potentially alter
the regulation of specific DNA-binding proteins for the treatment of diseases caused by aberrant
gene expression (16, 17).
As an ETS (E26 transformation specific) family member, PU.1 (Purine rich box 1) is a
transcription factor involved in normal hematopoiesis and a growing list of diseases. PU.1
regulates the expression of a large network of genes related to inflammation (18). For example,
PU.1 controls the expression of receptors for IL-2Rγ and IL-7Rα, and also regulates expression of
Toll-like receptors which may control the signaling pathways of certain auto-immune diseases (1923). In addition, down-regulation of PU.1 expression to 20% of normal cell levels is reported to
induce acute myeloid leukemia (AML) in mice, whereas a decrease to 50% of normal cell
expression retains normal hematopoiesis (24, 25). On the other hand, complete knock-down of
PU.1 causes severe dysfunction of hematopoietic stem cells and leads to cell death (24-27). Thus,
either raising PU.1 expression to normal functional levels or completely blocking the PU.1
transcriptional activity in AML cells is potential approach to the treatment of AML.
All ETS family transcription factors bind to DNA at the consensus binding site 5’GGAA/T-3’ with various flanking sequences. For example, the winged helix PU.1 targets the B
motif of the Ig2-4 enhancer (B promoter site: 5’-CCAAATAAAAGGAAGTGAAACCAAG-3’,
Fig. 1) and makes contacts with DNA by inserting a recognition helix into the major groove of the
consensus site while keeping adjacent protein loops in touch with the backbone of flanking DNA
sequences (28). The B DNA sequence is a template that has been widely used for the study of
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PU.1-DNA interactions. Targeting the 5’-side AT track of the GGAA site using naturally existing
distamycin demonstrated inhibition of PU.1 binding (29, 30).
To date, activation of gene expression through PAs has been done by conjugating PAs with
specific recruiting motifs like short peptides and protein-binding ligands (31-37). Previous studies
showed that the 3’ flanking sequence plays a critical role in PU.1-B DNA binding, with an
equilibrium (dissociation) constant KD = 2.68 ± 0.41 nM compared to KD = 240 ± 70 nM achieved
by simple mutation of the 3’ flanking GTG of B to TGG (38). Therefore, we designed a set of
PA analogs based on the recognition rules to bind to the 3’ flanking side (5’-GGAAGTGA-3’) of
the PU.1 binding site, aiming to interfere allosterically with PU.1 binding to DNA (Fig. 4.1). These
PAs are structurally modified and their binding properties to B DNA have been determined in
previous literature (39).
Herein, we report the cell-free studies of designed minor groove-binding PAs modulating
the major groove targeting PU.1. Previously, tandem hairpin PAs displaced the major groovebinding E2 protein of human papillomavirus from its cognate site. In that case, the viral protein
bends DNA about 180 ° and the ability of the minor-groove binding PAs to displace the major
groove-binding protein was attributed to (a) thermodynamics, since the PAs bind more tightly to
DNA than the protein, and (b) dynamic equilibria, in which each DNA ligand associates and
dissociates to its DNA target, allowing the tighter-binding ligand to bind the DNA no matter which
ligand is bound first (17). Our results show that nine out of ten PAs allosterically disrupt the PU.1DNA interaction with a linear correlation between PA binding affinity and inhibition efficacy. One
PA, FH1024, is not a PU.1 inhibitor and forms a FH1024-PU.1-B DNA trimer. Altogether, the
results have offered new insights into the effects of DNA modulation by PAs, deepened our
understanding of the molecular basis of small molecule-DNA-protein interactions and provided
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guidance for optimizing molecular design and consequently improving the efficiency and accuracy
of gene regulation in disease treatment.
4.3

Materials and Methods
4.3.1

DNA

DNAs:
The DNA oligomers in this study were purchased from Integrated DNA Technologies, Inc.
(IDT, Coralville, IA) with HPLC purification.
DNA sequence used for ESI-MS and EMSA:
5’-CCAAATAAAAGGAAGTGAAACCAAGCTCTCTTGGTTTCACTTCCTTTTATT
TGG-3’
The bold, underlined site is the PU.1 binding site, the PA target binding site is indicated in
red. The hairpin is shown in italic. The same sequence is used for SPR experiments but with a 5’biotin.
4.3.2

Polyamides synthesis and preparation

Compounds are synthesized and prepared as previously described (39).
4.3.3

PU.1 purification

Recombinant PU.1 ETS domain (murine residues 167 to 272) was expressed and purified
as reported previously (40, 41).The final protein product, which does not contain the His6
purification tag, was stored at 4 ºC. The protein is stable for at least a few weeks under this
condition. Protein concentration was determined by absorption at 280 nm using an extinction
coefficient of 22,460 M-1 cm-1.
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4.3.4

Surface Plasmon Resonance

In addition to the binding experiments, we have developed a novel SPR procedure to study
the effects of small molecules on protein-DNA interactions. The SPR experiments were carried
out on a four-channel Biacore T200 optical biosensor system (GE Healthcare, Inc., Piscataway,
NJ). The biotinylated DNA was immobilized on a sensor chip functionalized with streptavidin.
The first channel was used as reference channel and does not have DNA immobilized. The samples
contain a mixture of constant 50 nM PU.1 and different concentrations of PA. For the amount of
immobilized DNA, 50 nM PU.1 can reach steady state binding and RUmax. The PA concentration
(starting from 0 nM) increases as the number of the experimental flow cycle rises. In each cycle,
the sample was injected over the sensor chip surface at a flow rate of 50 µL·min -1. During the
sample flow, PU.1 and PA are competing or cooperating to form a complex with the DNA
immobilized on the sensor chip. The sensorchip was washed with pure buffer at the end of each
sample injection to help dissociate the existing complex. Then, 1 mM NaCl was injected as
regeneration buffer to dissociate any remaining complex and prepare the chip for the next cycle.
PA alone was injected in the last cycle for baseline subtraction and signal reference. The SPR
sensorgrams were generated immediately after finishing the experiments and were presented as a
function of response unit (RU) vs. time (Fig. 4.2). The resulting RU changes of PU.1 in the
presence of PA at equilibrium were then plotted against PA concentration (Fig. 4.3). The IC50
value, which represents inhibition efficacy, was determined at the PA concentration where 50% of
PU.1 is inhibited from binding to DNA. This experiment was performed in phosphate buffer (25
mM Na2HPO4, 400 mM NaCl, 1 mM EDTA and 0.05% v/v surfactant P20, pH 7.4, filtered and
degassed), which is compatible with both PU.1 and the PA.
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4.3.5

Electrophoresis Mobility Shift Assay

Electrophoresis Mobility Shift Assay (EMSA) was carried out as a complementary and
validation study. The samples were prepared in a buffer composed of 10 mM Tris (pH=7.4), 150
mM NaCl, 0.1 mM EDTA, 100 ng/µL BSA, and 10% v/v glycerol. 25 nM PU.1was mixed with
appropriate ratios of PA before 25 nM DNA was added. The samples were then loaded onto 12%
native polyacrylamide gel and run in 1x TBE (Tris-borate-EDTA) buffer. The gel was run for 3 h
at 120 V. It was then stained with SYBR Gold Nucleic Acid Gel Stain (Invitrogen, Carlsbad, CA)
for 20 min before visualization on a Typhoon FLA 9500 laser scanner.
4.3.6

Electrospray Ionization Mass Spectrometry

Both PU.1 and DNA were dialyzed against 150 mM NH4CH3CO2 buffer, pH 6.8, for one
week, with a total of three times buffer exchange. This step is carried out to eliminate the Na+
present in un-dialyzed DNA, which can form adducts resulting in complicated MS data that are
not readily interpretable. A stock solution of 0.5 mM each compound was made by dissolving the
compound in distilled deionized (DDI) water. The MS samples were prepared by mixing PU.1 and
DNA at 1 to 1 ratio at the desired concentration. Compounds for titration were prepared in separate
tubes and added to the pre-mixed PU.1-DNA. Immediately prior to injection, 5 µL methanol was
added to the sample to facilitate solution to gas phase transition. The total sample volume was 100
µL.
The MS experiments were performed on a Waters Micromass ESI-Q-ToF spectrometer
(Waters Corporation, Milford, MA, USA). Data were collected and analyzed using MassLynx 4.1
software. In positive ion mode, samples were injected at a rate of 5 µL·min-1 and scanned for m/z
range from 300-3000. The last two minutes of the mass spectral data were averaged and the
resulting spectrum was convolved to give the intact molecular mass. The instrument parameters
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were as follows: capillary voltage of 2500 V, cone voltage of 20 V, extraction voltage of 2 V,
desolvation temperature of 100 oC, and source temperature of 70 oC. Nitrogen was used as
nebulizing and drying gas.
4.4

Results
4.4.1

Quantitative evaluation of PU.1 inhibition by PA

Cell-free studies of competitive binding of PAs and PU.1 to λB DNA were carried out by
SPR. The SPR method developed by our group for inhibition studies is efficient, label-free, and
acquires inhibition efficacies that agree with other methods (29). The inhibition of PU.1 by a PA
was evaluated by injecting 50 nM PU.1 to establish a high molecular weight baseline, and injecting
PA alone to establish a low molecular weight baseline. To determine binding and inhibition
parameters, increasing concentrations of PA were injected onto the sensorchip surface, which had
been immobilized with target DNA, while maintaining a fixed concentration of 50 nM PU.1. The
signal or response unit (RU) generated in SPR is proportional to the molecular weight of the bound
ligand, in this case, PU.1 or PA or both. Given that the molecular weight of PU.1 (12 kDa) is much
larger than that of the present PA library (around 1250 Da on average), the RU caused by binding
of PU.1 is much higher than that caused by the binding of PA. This molecular weight-dependent
RU difference can lead to three different outcomes when a PA is present during PU.1-DNA
binding: 1) the RU drops if PA replaces PU.1 upon binding DNA; 2) the RU stays the same if PA
fails to compete with PU.1 for DNA; 3) the RU rises as the binding of PA increases if PA and
PU.1 bind to DNA simultaneously or cooperatively.
Sensorgrams reflecting the real-time binding activity of each sample (PA and PU.1
mixture) were generated. As shown in Fig. 4.2, for each PA depicted there, the RU decreased as
the concentration of PA increased, indicating that the PAs competed with and eventually replaced
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PU.1 on the DNA. For strong inhibitors such as FH1028 and KA2115, the RU descended rapidly
with a slight increase in PA concentration. On the contrary, much smaller RU changes were
observed for the weak inhibitors, KA2114 and FH1026, even with large increases in PA
concentration. It is noteworthy that for weak inhibitors like FH1026, the RU change plateaued as
the PAs reached certain concentrations. This is likely due to the combination of specific and nonspecific binding of the molecules when presented in excess. Because the PU.1 binding site
typically occupies 10-16 bp of the 23-bp DNA sequence, the additional, untargeted base pairs are
exposed to excess PA. In addition, due to the degenerate recognition of A and T by pyrrole (5-8)
as well as the tolerance of imidazole for interacting with bases other than G (39, 42-44), excess
PA tends to bind non-specific DNA sites.
To determine the IC50 value (inhibition efficacy), the PA concentration at which 50% of
PU.1 binding is inhibited, the RU data were plotted as a function of PA concentration (Fig. 4.3).
Table 4.1 is a summary of PAs with their binding affinities (previously determined (39)) as well
as their corresponding inhibition efficacy (IC50) values. The PAs exhibited strong inhibition with
a number of IC50 values in the single-digit nM range. As shown in Table 4.1, there is a strong
correlation between the IC50 and KD values. To further quantify the correlation, the log values of
IC50 were plotted as a function of log (KD), and showed a linear correlation between binding
affinity and inhibition efficacy (Fig. 4.4). This linear correlation implies that these PA analogs
bind to DNA in the same manner. More specifically, for eight-ring PAs that have no more than
two β inserts, if the two β inserts are not next to each other on the same strand, the modified PAs
still recognize the same DNA sites. This finding removes our concern about future eight-ring PA
design that the molecule might change its cognate binding site after β modification.
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4.4.2

FH1024 is an outlier and does not inhibit PU.1-DNA binding

FH1024 is a medium-affinity binding agent modified from the parent PA, KA 2035, with
the Py/Py substituted by β/β and tetramethylguanidinium (TMG) as the N-terminus (Fig. 4.1).
According to the correlation established (Fig. 4), FH1024 was anticipated to inhibit PU.1-DNA
binding with moderate inhibition efficacy of IC50 ≈ 50 nM. To our surprise, when the mixture of
FH1024 and PU.1 flowed through the sensorchip surface, the resulting RU did not decrease as it
did with the other PAs under the same assay conditions. Instead, a RU increase occurred as the
concentration of FH1024 increased (Fig. 4.5a). The observation leads us to suggest that FH1024
is not a PU.1 inhibitor but can bind simultaneously to DNA with PU.1. Furthermore, the difference
of RU (ΔRU) caused by binding of the mixture is more than the ΔRU resulting from FH1024
binding alone, and this could indicate that FH1024 promotes additional PU.1-DNA binding. To
further investigate the binding behaviors of PU.1-FH1024 mixture, different salt concentrations
were used. As shown in Fig. 5a, within the salt concentration range used, the RU generated by
flowing of FH1024-PU.1 mixture increased as the concentration of FH1024 went up, corroborating
the assumption that FH1024 and PU.1 bind to DNA simultaneously. The idea of FH1024
promoting PU.1 binding is strongly supported by the SPR results at 450 mM NaCl. Compared to
the RU at lower salt concentrations, PU.1 binding was significantly reduced at 450 mM NaCl.
When FH1024 was added, however, the binding RU value significantly increased and eventually
reached saturation at essentially the same RU level (approx. 140 RU) as at the lower salt
concentrations. This clearly indicates that FH1024 is a promoter or weak agonist of PU.1 binding.
The slight variation of RU values at saturation in Fig. 4.5 is due to the gradually reducing binding
capacity on the sensor chip with time and usage.
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To investigate if simultaneous binding is sensitive to the order of addition, in other words,
if PU.1 still binds when FH1024 pre-occupies its binding site, we switched the titration sequence
by keeping the concentration of FH1024 constant at 50 nM while increasing the concentration of
PU.1 in each flow cycle. If FH1024 inhibited the binding of PU.1, then the injection of PU.1 onto
a sensor chip pre-occupied with FH1024 would hardly cause any change in RU, especially at low
concentrations of PU.1. In this experiment, the PU.1 mixture sample was injected over the sensor
chip pre-mixed with FH1024 and the resulting sensorgrams are shown in Fig. 4.5b. The steady
increase in binding RU confirms that PU.1 binds to DNA in the presence of FH1024. Similarly,
under a gradient of salt concentrations, RU consistently increased as PU.1 concentrations went up
and the RU value at saturation stayed relatively constant, indicating potentially cooperative
binding of PU.1 and FH1024 in the major and minor DNA grooves.
4.4.3

Electrophoresis Mobility Shift Assay (EMSA) confirms that FH1024 is not

inhibiting PU.1-DNA binding
To test our observation further that PU.1 and FH1024 bind simultaneously to DNA, with
enhanced PU.1 binding promoted by FH1024, the interactions of λB-PU.1, λB-FH1024, λB-PU.1FH1024, and λB-PU.1-FH1028 were explored on native polyacrylamide gels. FH1028 was used
because it is structurally very similar to FH1024 and showed strong inhibitory activity in SPR,
therefore is a good negative control for FH1024. As shown in Fig. 4.6, λB DNA gives a very thick
band at the bottom (lane 1, red arrow). It is noticeable that in lane 1, there is an additional band
(blue arrow) besides λB DNA. This is very likely a duplex of two hairpin λB DNAs with open
hairpin. λB DNA and PU.1 formed a 1:1 complex (lane 2, green arrow); The duplex λB DNA and
PU.1 complex resulted in two bands (blue arrows), one with PU.1 bound on one site, the other
with PU.1 bound on both binding sites of the duplex DNA. There is also an additional band at the
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top of the gel resulted from non-specific binding of PU.1. Because the molecular weight of FH1024
is much smaller than λB DNA, the binding of λB and FH1024 did not result in any mobility shift
of the complex from DNA alone at the experimental resolution (lane 3, red arrow); When λB DNA,
PU.1, and FH1024 mixture ran through the gel (lanes 4-6), clear bands of λB DNA-FH1024 (red
arrow) and λB DNA-PU.1 complex (green arrow) appeared. The fraction of bound λB DNA in
lane 4 and 5 are approximately equal to that of lane 2, which is around 0.28. When we raise the
FH1024 ratio to λB: PU.1:FH1024=1:1:4, shown in lane 6, the fraction bound increased to 0.34
and the intensity of duplex λB DNA-PU.1 increased significantly (lane 6, blue arrow). These
results suggest that FH1024 did not impede binding between λB and PU.1 and to some extent,
promoted PU.1-DNA binding.
On the other hand, when FH1028 was added to λB DNA and PU.1 mixture, the band of
both λB-PU.1 and duplex λB-PU.1 complex disappeared almost completely even at ratio λB:
PU.1:FH1028=1:1:1 (lane 7). At ratio λB: PU.1:FH1028=1:1:2, the band became even fainter,
indicating that FH1028 is a strong inhibitor for PU.1, in agreement with SPR results. It is
noteworthy that in the mixture of all three components (lanes 4-8), the DNA band started diffusing
in the gel. This is probably because of the DNA conformation adjustment caused by the
competition between PA and PU.1 binding and the occupation of the dye staining site on DNA by
bound polyamide. Though we were unable to detect λB-PU.1-FH1024 trimer complex due to both
small molecular weight of FH1024 and the low resolution of the gel, the consistent result validates
the observation in SPR that FH1024 is not inhibiting PU.1-DNA binding.
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4.4.4

Analyzing λB-PU.1-FH1024 using Electrospray Ionization Mass Spectroscopy

(ESI-MS)
ESI-MS was performed to further investigate the mechanism of action between PA and the
PU.1-DNA complex. With high resolution, mass accuracy and sensitivity, mass spectrometry
possesses the capability of distinguish between the PU.1-λB DNA dimer and PU.1-λB-PA trimer,
despite the relatively small difference in molecular weight between the two complexes. Shown in
Fig. 4.7a is the 1:1 mix of PU.1-λB DNA; no significant amount of free PU.1 or free DNA was
detected. When we added FH1024 at ratio λB: PU.1: FH1024 = 1:1:1, a small peak corresponding
to the total mass of λB+PU.1+FH1024 appeared (Fig. 4.7b), which is indicative of the presence of
the trimer. The fact that no free PU.1 or free DNA showed up in the spectrum confirmed our other
observations and indicated that FH1024 binding did not force PU.1 from the DNA. Furthermore,
as the concentration of FH1024 increased, more trimer formed, as indicated by the increase in MS
signal intensity of the trimer peak, while no free PU.1 or DNA was released from the complex
(Fig. 4.7c-d). These results clearly demonstrated that FH1024 does not disrupt the interface of
PU.1-DNA but forms λB-PU.1-FH1024 trimer when added to the protein-DNA complex.
To compare the results of FH1024 with a PU.1-DNA inhibitor, samples consisting of λB,
PU.1, and FH1028 were also prepared and examined through MS testing. At the ratio λB: PU.1:
FH1028 = 1:1:1, both free PU.1 and PA-bound DNA were detected due to the strong inhibition
efficacy of FH1028 (IC50=1.2 nM, Fig. 4.7e). Because FH1028 is a very strong DNA binder
(KD=0.16 nM), all free DNA was occupied by FH1028 as the DNA-FH1028 complex shown in
the mass spectrum. At ratio λB: PU.1: FH1028 = 1:1:2, free PU.1 and the DNA-FH1028 complex
were obtained. The small peak corresponding to the total mass of λB+PU.1+FH1028 could be the
result of non-specific binding of FH1028, since the concentration used in MS (10 µM) is much
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higher than that in SPR (nM), 63,000 times the IC50, and PU.1 only occupies around 10-16 bp
along the 25 bp λB. For a strong binder like FH1028, at such high concentration and with the
availability of extra binding sites, non-specific binding is almost inevitable. Thus, with a
combination of biophysical and analytical methods, we have proved that FH1024 is exceptional
among the systematically designed PA analogs as it does not disrupt PU.1-DNA binding but is
able to bind to DNA-PU.1 dimer complex in a manner that favors the formation of a DNA-PU.1FH1024 trimer complex.
4.4.5

FH1024 binds to the same DNA site as other PA analogs

We established previously that our systematically designed, inhibitory PAs bind to DNA
at the same binding site and there is a positive linear correlation between their binding affinity and
inhibition efficacy on PU.1. Given that FH1024 enhances PU.1 binding and binds to DNA
simultaneously with PU.1, whether FH1024 kept the same DNA-binding site as the inhibitory PAs
became a critical question to address. To probe this question, two competition-binding SPR
experiments were conducted. The samples prepared for these two experiments were: (1) a mixture
of 50 nM PU.1, 10 nM FH1028 and increasing concentrations of FH1024, and (2) 50 nM PU.1,
50 nM FH1028 and increasing concentrations of FH1024. Since FH1028 is a strong binder (ten
times stronger than FH1024) and an effective inhibitor, FH1024 at low concentration would not
be able to bind to DNA in the presence of excess FH1028, whereas high concentrations of FH1024
would have the capacity to overcome the inhibitory effect of FH1028. The sensorgrams of the two
competition assays are shown in Fig. 8. As expected, in the presence of constant 10 nM FH1028,
it takes at least 50 nM FH1024 to start binding to DNA. Meanwhile, for DNA pre-occupied by 50
nM FH1028, more than 500 nM FH1024 is needed to overcome the inhibitory effect of FH1028.
These results suggest the direct competition of FH1024 with FH1028 at the same DNA binding
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site. This is expected since all of the PAs in Fig. 4.1 were designed to bind to the same site of the
λB promoter DNA. Importantly, as shown on the sensorgrams, when FH1024 started binding to
DNA, the RU began rising, meaning the molecule has the power, at high concentration, to reverse
the strong inhibitory effect caused FH1028 and coexist with PU.1 on the DNA.
4.5

Discussion
4.5.1

Molecular basis of PU.1 inhibition by PA

Our ultimate goal is to apply small molecules such as PAs as therapeutic agents. It is,
therefore, important to understand the biological/pharmacological activities of PAs to guide future
drug design. The inhibitory effects of PAs have been explored in several biological systems (37,
45-47). The conformational change of DNA upon PA binding can be classified into three
categories: direct perturbation to the PA binding site in the minor groove, proximal allosteric
perturbation in the major groove, and distal allosteric perturbation outside of the PA binding site
(45). Good inhibitors of PU.1 are achievable at the 5’ side of the PU.1 binding site on λB promoter
DNA. Yet no inhibitors at the 3’ side were explored and the 3’ side has been shown to be critical
for PU.1 binding (38). Thus, the current PAs are designed to target the 3’ flanking sequence of the
PU.1 binding site (Fig. 4.1). The PAs synthesized exhibit DNA binding affinities ranging from
0.16 nM to 79 nM, very competitive to the major groove binding PU.1 (KD = 7 nM) under the
same conditions. As the SPR results show, most of the PAs demonstrated very strong inhibition
with nanomolar IC50 values, meaning that distal allosteric inhibition of PAs is relevant to the 3’
flanking bases of PU.1 binding site.
Previous X-ray structure studies on hairpin PAs binding to the nucleosome core particle
(NCP) revealed a large distortion distal to the PA binding sites and long-range perturbations in the
structure of the NCP (48, 49). Another such study on the structure of an eight-ring, cyclic PA
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bound to DNA demonstrated that the PA causes DNA distortion by widening the minor groove ~4
Å while compressing the major groove, with an additional distortion seen as bend of the helix axis
> 18º toward the major groove (45, 50). These types of large distortion in DNA conformation are
likely the driving forces that disrupt the interface between PU.1 and its cognate site. Strong
inhibitors such as FH1028 and KA2115 are able to anchor firmly inside the minor groove and
induce a long-lasting (low dissociation rate, long residence time) DNA conformation change,
whereas weak inhibitors such as KJK6162 and FH1026 have very fast on and off rates, making
them uncompetitive with PU.1 for the DNA binding site. The fact that binding affinities of PAs
are positively, linearly correlated with the inhibition efficacies leads us to suggest that the
inhibitory PAs all bind at the same target site, the site they were designed for, and further indicates
that all PAs bind in the same mode.
4.5.2

Molecular basis of FH1024-PU.1-DNA trimer formation

The interaction between PU.1 and DNA is greatly dependent upon DNA micro structure.
Observation of the FH1024-PU.1-DNA trimer indicates that the FH1024 complex is different from
the other PAs in this study. Among those, KA2040 and FH128 are close analogs to FH1024, both
of which are strong binder and inhibitors. FH1024 presents a lower binding affinity than its close
analogs (KD =1.65 nM) primarily, we suspect, due to its high flexibility in the β/β composition
which renders the inner structure more adaptable to a range of structures than its analogs. In
addition, we must consider the electrostatic interactions generated by both the highly positively
charged N- and C-termini and the bulk of the N-terminal tetramethylguanidinium found in
FH1024, all of which may make the overall structure less able to form stable complexes with the
target sequence. Though constrained by the hairpin linker, the two strands of FH1024 on the open
side (the non-hairpin side) might well not be stacked. In a forward binding mode (where the N-

109

terminal to C-terminal PA vector aligns with 5’-3’ DNA vector, Fig. 4.9), when buried in the minor
groove, the positively charged, bulky TMG clashes not only with the minor groove wall, but it also
reaches the exocyclic amine of guanine (Fig. 4.9) within the PU.1 binding site. Thus TMG is
possibly exposed to repulsive electrostatic forces from both G (from DNA) and the C-terminal Ta
tail. It is noteworthy that both the N-terminal TMG and C-terminal Ta tail extend into the minor
groove of the central PU.1 binding site and are in close proximity to the middle bases (Fig. 4.9).
For a well-stacked hairpin PA like FH1028, such binding forces a further widening of the minor
groove due to the plasticity of DNA, making PU.1 binding unfavorable. For FH1024, which has
flexible N- and C-termini that cannot fit into the minor groove in a well-stacked manner, in the
presence of PU.1, the upper (N-terminal) strand of bound FH1024 might float out of the minor
groove or even flip away from the PU.1 binding site, leaving the lower (C-terminal) strand inserted
in the minor groove. Therefore, the binding of FH1024 may not cause as significant a structural
change as the inhibitory PAs, preventing it from disrupting the binding of PU.1 and DNA.
It was reported previously (51) that the Dp tail of an eight-ring PA, when positioned in
proximity to the cognate site of the transcription factor extradenticle (Exd), would facilitate ExdDNA binding, possibly because the charge and steric repulsion between Dp and exocyclic amine
of guanine favor displacement of the bases toward Exd in the major groove (51). In our case, the
Ta tail on the lower strand of FH1024 is placed in close proximity to the 5’-GGA-3’ bases of PU.1
binding site, making similar contacts to the previously reported Dp with the minor groove floor.
Thus, the binding of FH1024 does not disrupt the PU.1-DNA complex, but promotes binding of
PU.1, owing in part to electrostatic and steric interactions between Ta and the exocyclic amine of
the guanine (Fig. 4.9) in the minor groove.
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4.6

Conclusion
Many diseases are found to be likely caused by the aberrant expression of certain genes.

Abnormal accumulation and/or depletion of transcription factors that are vital in regulating gene
expression could be the key step in contracting such diseases. A breakthrough to probe this issue
is the use of DNA-binding small molecules to modulate once-undruggable transcription factors.
PAs have been studied for this purpose for many years and most of the PAs, if capable of affecting
protein-DNA binding, are inhibitors unless conjugated with specific recruiting peptides or other
ligands. Molecules that are small in size are generally more soluble, efficient in permeating cells
and accessing chromosomes than large molecules. Smaller molecules are also economically more
efficient in that they are easier to synthesize. In this work, we have reported the inhibitory effect
on transcription factor PU.1-DNA binding of nine out of ten of the designed hairpin PAs. We have
found that one of the PAs, FH1024, is not an inhibitor and appears to be among the first unmodified
PAs to have such stimulatory effect. The molecule FH1024 binds to DNA simultaneously and
potentially cooperatively with PU.1. The interactions likely require a particular binding mode of
PA and appropriate register with the PU.1 binding site. More structural and computational studies
are in need to better understand the molecular basis of these interactions, thus providing guidance
for improving and optimizing the design of additional such molecules.
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Tables and Figures
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Figure 4.1 Schematic representation of a set of synthesized hairpin polyamides and λB DNA.
The polyamides are classified into two modified groups: β-alanine inserts (red) and cationic
substitutions (blue). The simplified representation of parent PA KA2035 is shown below its
structure and the numbering scheme applies to all PAs.
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Figure 4.2 SPR sensorgrams of PU.1 and PAs (exclude FH1024) binding to λB DNA.
The black line on the top (highest RU) of each sensorgram represents the injection of 50
nM PU.1. The silver line at the bottom (lowest RU) of each sensorgram represents the
binding of PA alone. The legend indicates the concentrations of corresponding PAs. The
sensorgrams are arranged in a manner by which inhibition efficacies decrease from left to
right and from top to bottom.
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Figure 4.3 Plots of fraction bound for PU.1 vs. polyamide concentration to determine IC50 values.

Table 4.1 Comparison, for PAs, of DNA binding affinities vs. PU.1 inhibition efficacies (IC50
values) on λB DNA.

KD (nM)

IC50 (nM)

0.49

3.6

0.54
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Figure 4.4 Log-log plot establishes a linear correlation between DNA binding affinities of PAs and
PU.1 inhibition efficacies (IC50 values) on λB DNA.
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a
50 nM PU.1
50 nM FH1024

50 nM PU.1

b

50 nM FH1024

Figure 4.5 Simutaneous binding of FH1024 and PU.1 to λB DNA.

a) Flow of increasing concentration of FH1024 mixed with constant 50 nM PU.1 onto
immobilized DNA. The legend indicates the concentrations of FH1024. In each sensorgram of
panel for a, the black line (before RU increases) represents binding of 50 nM PU.1 alone; the
separated silver line at the bottom results from 50 nM of FH1024 binding alone. b) Flow of
increasing concentration of PU.1 mixed with constant 50 nM FH1024 onto immobilized DNA.
The legend indicates the concentrations of PU.1. In the sensorgrams of panel b, the black line
at the bottom represents binding of 50 nM FH1024 alone.
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Figure 4.6 Effect of FH1024 on PU.1-DNA binding.
Lanes 4-6 show different ratios of FH1024 added to PU.1-λB DNA complex. Lanes 7-8 are
comparisons with strong inhibitor FH1028. Red arrows indicate bands corresponding to λB
DNA or λB DNA-PA complex. Green arrows point to bands from λB DNA-PU.1 complex.
Blue arrows show the bands of duplex λB DNA-PU.1 complex with PU.1 on one or both
binding sites. Black arrow indicates non-specific binding of PU.1 on DNA.
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Figure 4.7 ESI-MS showing: (b-d) the formation of the FH1024-DNA-PU.1 trimer and (e-f) the
inhibition of the PU.1-DNA complex by FH1028.
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Figure 4.8 Binding by SPR of FH1024 with fixed concentrations of PU.1 and FH1028.
The bright green line represents FH1028. The legend indicates the concentrations of
FH1024. In the left panel, FH1028 was kept at 10 nM. In the right panel, the
concentration of FH1028 is 50 nM.
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Figure 4.9 Schematic illustration of the relative positions of the cognate sites for
PU.1 and FH1028.
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5

CONCLUSIONS

This dissertation has investigated the systematic design and synthesis of a set of eightring hairpin polyamides as well as a new class of Pyr-AzaHx hybrid polyamides. Their DNA
binding affinities and specificities of these molecules were evaluated. The effects of the eightring hairpin polyamides on the transcription factor PU.1-DNA interactions were explored.
The results altogether have deepened our understanding on the molecular recognition between
small molecules and DNA and also broadened our view on the molecular interactions among
small molecules, DNA, and PU.1.
More specifically, the use of SPR in determining the DNA binding affinity and
specificity of both polyamides and PU.1 with high accuracy has demonstrated that SPR is a
well-established method that is applicable to such binding studies. Modifications of eight-ring
hairpin polyamides by β-alanine and N-terminal cationic group have diverse effects on the
DNA binding properties. Close comparison revealed a pattern of how the number and position
of β-alanine affect the binding affinity and specificity. The pattern can be used as reference
when predicting the interactions of newly designed molecules.
Design and synthesis of Pyr-AzaHx hybrid polyamides was carried out in order to
expand the DNA recognition sites of small, fluorescent molecules to facilitate cell studies.
Evaluation of the DNA binding properties of these molecules showed that the modification
did not specifically recognize the proposed binding site, but exhibited enhanced binding
affinity compared to the last generation of such molecules. Even though more efforts are in
need to extend the DNA recognition repertoire, the enhanced binding properties of these
modified molecules provide valuable guidance for the design of the next generation hybrid
polyamides.
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This dissertation investigated the effects of the eight-ring hairpin polyamides on the
transcription factor PU.1-DNA interactions to prepare for the biological application studies of
polyamides. Most of the polyamides either have no effect or inhibit the binding of PU.1 to
DNA. The inhibition efficacy of polyamides was found to be positively correlated to their
binding affinity. A potential PU.1 binding enhancer molecule was identified. Enhancing of
protein binding is often achieved by attaching enhancing agents to polyamides and is rarely
seen in polyamide alone. These encouraging results added to the driving force of our
continuing understanding of the molecular mechanisms of action of these interactions.
Polyamides are class of promising candidates for the treatment of cancer, viral, or
bacterial infectious diseases. This dissertation undertook the fundamental work of furthering
the understanding of polyamide-DNA interactions as well as polyamie-DNA-PU.1
interactions to establish solid basis for the biological and clinical applications of polyamides.
Their possession of high DNA binding affinity and specificity has enabled them to efficiently
affect gene expression through interfering with transcription factors. In addition, unlike other
peptide or chemical drugs, polyamides are resistant to the biological degradation by nucleases.
Achieving efficient nuclear localization and low long-time toxicity would be greatly helpful
to unleash the potential of polyamides as medicinal therapeutics.

